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ABSTRACT 
Methylation of cytosine bases within CpG dinucleotides (5meC) of DNA is an 
epigenetic modification that acts as an important regulator of genomic stability and gene 
expressivity. Genome-wide changes in methylation may be associated with lineage-
specific changes in gene expression profiles during development and some cell-based 
pathologies, including oncogenesis.  
Genome-wide loss of methylation is reported to accompany epigenetic reprogramming 
of the embryo immediately following fertilisation and also during the formation of 
primordial germ cells. There are also reports of a process of global demethylation 
commonly associated with the initiation of oncogenesis. The demethylation event 
reported to occur in the embryo following fertilisation (particularly of the paternally-
derived genome) is considered to be an active process (occurring in the absence of DNA 
replication). As such, it served as the main tool in attempts to identify an active 
mammalian demethylase. Despite many proposed candidates, several decades of 
investigation have yet to provide definitive identification of an active demethylase in 
animals.  
Recent re-analysis of the methylome of the early embryo has called into question the 
extent of demethylation that occurs following fertilisation. One analysis showed that 
zygotic maturation initiates a process of progressive antigenic masking of 5meC. This 
gives the impression of demethylation, but modification of the staining technique to 
enhance antigen retrieval revealed a persistence of 5meC staining levels throughout 
early development. This result was supported by a base-level analysis of the methylome 
by reduced representation bisulfite analysis, which did not reveal the pattern of loss of 
5meC that is predicted by earlier models. These results call for a re-evaluation of long-
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standing models of epigenetic reprogramming during development and the role for 
active demethylation in this process. It also questions the reliability of the 
immunological methods that are currently used for whole-cell analysis of the 
methylome.  
This thesis examines the conditions required for reliable immunological analysis of 
global patterns of CpG methylation. It used a widely studied somatic cell model (mouse 
embryonic fibroblasts) and examined the effects of various cell growth states and the 
consequences of exposure of cells to various genotoxic stresses on staining of 5meC.  
The study shows that much of the nuclear 5meC in fibroblasts was not detected using 
current staining techniques for this antigen. This resulted in an underestimation of the 
total level of 5meC staining and also resulted in the detection of artefactual patterns of 
nuclear localisation of staining. When cells were subjected to a further process of brief 
epitope retrieval by tryptic digestion, significantly higher rates of 5meC staining were 
revealed and much of this extra staining was in the form of multiple distinct 5meC-
intense foci scattered throughout the nucleus. The extent of trypsin-sensitive masking of 
the antigen was greater in proliferative than quiescent cells, and also changed following 
genotoxic stress.  
 
The 5meC-intense staining foci observed in fibroblasts were found to be primarily 
associated with heterochromatin (stained for HP1-β). An unexpected complexity in the 
relationship between the conformation of heterochromatin and the capacity to detect 
DNA methylation by conventional immunolocalisation was observed. The results infer 
that the dynamic changes in heterochromatin that occurred with different growth states 
of the cells may underlie the trypsin-sensitive changes in the levels DNA methylation 
detection by immunolocalisation.  
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The 5meC-specific binding protein (MBD1) is commonly used as a proxy for the 
measurement and localisation of 5meC in cells. This study showed that MBD1 was also 
the subject of some epitope masking in fibroblasts. The levels and patterns of staining of 
this antigen changed markedly after epitope retrieval by brief tryptic digestion. Staining 
under these conditions showed that there was extensive co-localisation between 5meC 
and MBD1, but some regions of nuclear 5meC staining did not stain for anti-MBD1. 
Importantly, some heterochromatic foci co-stained for both antigens while others did 
not. These results further illustrated the unexpected epigenetic complexity of these 
regions of the genome that was revealed by these improved methods of 
immunolocalisation of the antigens. 
 
This study provides a detailed re-analysis of the methods required for reliable 
immunolocalisation of the 5meC antigen in a widely-used somatic cell type. It shows 
that a cell’s growth state and genomic integrity cause changes in the extent of antigen 
masking and this can create a misleading interpretation of changes in global methylation 
levels. The masking was accounted for by trypsin-sensitive proteins, indicating that it 
probably arises from changes in the types or conformation of proteins within chromatin 
that occur with changes in the cell’s growth state. It also shows that this masking 
primarily affected the detection of 5meC within heterochromatin.  
 
These results, together with recent evidence of limitations to the ‘gold-standard’ forms 
of methylation analysis (bisulfite or restriction analyses), point to the need for caution in 
the interpretation of the apparent global changes in methylation as a mechanism of 
epigenetic control.  
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1. CHAPTER 1: LITERATURE REVIEW 
1.1. Introduction 
Epigenetic regulation of gene expression is considered to be encoded by mitotically 
heritable modifications to eukaryotic chromatin. It results in stable changes in gene 
expressivity without any alterations to the DNA nucleotide sequence (Bjornsson et al., 
2004; Morgan et al., 2005).  
DNA methylation is one important epigenetic mechanism. It results from the addition of 
methyl groups (-CH3) to 5´-cytosine, most commonly within CpG (-C-phosphate-G-) 
dinucleotides of DNA. This modified nucleotide is called 5-methylcytosine (5meC) and 
was first discovered in 1904 (Wheeler and Johnson, 1904). CpGs are predominantly 
methylated with the exception of those in the CpG islands in the promoter regions of 
genes. DNA methylation may regulate gene expression during embryogenesis and 
development (Bar-Nur et al., 2011; Esteller, 2007; Simonsson and Gurdon, 2005; Zhao 
et al., 2013). DNA methyl-transferases (DNMTs) and Methyl-CpG-Binding Proteins 
(MBPs) are involved in the process of DNA methylation.  
DNA hypermethylation occurring mainly at gene promoters is associated with 
repressing gene expression, whereas DNA hypomethylation is associated with gene 
expression (Bar-Nur et al., 2011; Bocker et al., 2011). There is currently a relatively 
good understanding of the processes of controlling methylation, although the regulation 
of loss of methylation is far less well understood.  
CpG dinucleotides may be demethylated either by passive or active processes. Passive 
demethylation is a DNA replication-dependent mechanism (Kagiwada et al., 2012; Patra 
et al., 2008), and it occurs through asymmetric cell division, whereby the newly 
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synthesized DNA strand fails to undergo maintenance methylation (Stromberg, 2012). 
A range of mechanisms for replication-independent active demethylation have been 
proposed. Most of these involve the DNA repair pathways (Cortellino et al., 2011; Guo 
et al., 2011; Hashimoto et al., 2012; Kress et al., 2006), yet an enzymatic pathway 
unequivocal proven to catalyse this process has not been identified in animals. Since 
active loss of methylation is considered critical the epigenetic control of embryo 
development and is also implicated in some pathology, including oncogenesis, this 
limited understanding of demethylation constrains our understanding of epigenetic 
regulation.  
The most widely accepted example of global demethylation is the reported loss of 5meC 
from the paternally-inherited genome (compared to that inherited from the oocyte) 
immediately following fertilisation (Iqbal et al., 2011; McLay and Clarke, 2003; Silva et 
al., 2011). Evidence for this process has largely relied upon immunolocalisation of 
5meC in the zygote. This asymmetric demethylation has been widely used as a tool for 
attempts to indentify and characterising putative CpG demethylases. The evidence in 
support of this round of demethylation, however, has recently been called into question.  
Systematic analysis of the process found that the reports of loss of methylation in the 
zygote acutely resulted from a progressive masking of the antigen during zygotic 
maturation (Li and O'Neill, 2012). This masking was accounted for by the protein 
components of the nucleus and after brief tryptic digestion a large increase in 5meC 
staining became evident. Using this modified method of epitope retrieval it was found 
that 5meC persisted throughout zygotic maturation and the reported asymmetry between 
levels of methylation between the maternally and paternally inherited genomes were no 
longer evident (Li and O'Neill, 2012).  
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It is recognised that the processes of zygotic maturation involved major changes in 
chromatin organisation and it is likely that these changes account for the increased 
trypsin-sensitive masking of 5meC. Yet, changes in chromatin structure are common in 
many cell processes. Chromatin structure changes with the cell-cycle and as the cell 
undergoes metabolic activation in response to environmental cues and stresses. The 
processes of DNA replication and repair after damage are also associated with major 
alterations to chromatin composition and structure.  
This thesis will address the question of whether the marked change in 5meC epitope 
masking detected during zygote maturation is unique. It will examine the effects of 
transitions in chromatin structure associated with changes in a somatic cell’s growth 
status and in response to various forms of DNA damage on the detection of 5meC by 
immunological detection techniques. The extent of trypsin-sensitive masking will be 
assessed, and the conditions required for faithful detection by immunolocalisation of 
5meC under a range of conditions will be defined. The study aims to provide a firm 
basis for providing tools for the rapid global analysis of 5meC in cells and the well 
established model cell type – primary mouse embryonic fibroblasts are used to provide 
maximum utility of the results.  
1.2. DNA methylation 
1.2.1. The DNA methylation machinery 
Methylation of CpG dinucleotides in the genome is catalysed by the enzyme mediated 
transfer of methyl group of S-adenosylmethionine (SAM) to the 5′-carbon of cytosine. 
This reaction is catalysed by DNA methyltransferase enzymes (Grønbæk et al., 2007) 
(Figure 1-1A and B). The DNMT enzymes include three major groups, DNMT1, 
DNMT3 and DNMT2. They play roles in de novo methylation of DNA (Hata et al., 
4 
 
2002; Okano et al., 1999), maintenance of DNA methylation (Feng et al., 2010), X 
chromosome inactivation (Vasques et al., 2005), gene activation or inactivation (Robert 
et al., 2003; Vasques et al., 2005), and RNA processing in cellular stress (Schaefer et 
al., 2010; Thiagarajan et al., 2011). The resulting methyl-group lies within the major 
groove of the DNA double-helix (Vargason et al., 2000) and there it can act as a 
docking site for binding proteins. It is hypothesised that the resulting complexes 
regulate access of transcription factors to the genome (Burgers et al., 2002; Chen and 
Riggs, 2011) hence regulating gene expressivity. 
 
Figure 1-1. Cytosine methylation.  
Methylation occurs (A) in cytosines residing in the CpG-rich nucleotides in the genome, 
and this reaction is catalysed by DNA methyltransferase enzymes (DNMTs) through (B) 
a carbon-carbon covalent bond between methyl group of S-adenosylmethionine (SAM) 
and 5′ carbon of the cytosine. Adapted from Grønbæk et al. (2007). 
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1.2.1.1. DNMT1  
The DNMT1 family has three main isoforms: a form found predominantly within 
somatic cells (DNMT1s, also known as DNMT1) (Ratnam et al., 2002): a form found in 
female germ cells (DNMT1o): and a form in male germ cells (DNMT1p)  (Mertineit et 
al., 1998; Ratnam et al., 2002).  
DNMT1 is considered to be primarily responsible for the maintenance of DNA 
methylation. DNMT1 has a strong binding preference for hemi-methylated CpGs 
created during DNA replication of somatic cells, and catalyses methylation of the hemi-
methylated CpG islands by the recruitment to replication fork of DNA embedded in 
euchromatin in early S phase (Lan et al., 2010) (This reaction is also implicated in 
passive demethylation and is discussed in section 1.3.1.1). The role of DNMT1 in 
maintenance methylation provides a hypothetical model for retaining epigenetic 
memory within a lineage across many cell-generations (Bar-Nur et al., 2011; Bird, 
2002; Wolf, 2013). DNMT1 has also been implicated in replication-independent 
methylation occurring during G2 and M phases of the cell-cycle (Easwaran et al., 2004; 
Shimamura and Ishikawa, 2008).  
The gamete-specific forms, DNMT1o and DNMT1p, are believed to play specific roles 
in gametogenesis. DNMT1o exists only in the cytoplasm of oocytes (Jeong et al., 
2009b), but it migrates from cytoplasm to nucleus during early embryo development 
and this dynamic movement is independent on DNA replication, transcription, protein 
synthesis and cell contact (Doherty et al., 2002). Dnmt1o has been recently found to 
interact with DNMT1-associated protein-1 (DMAP-1) in mice and this protein may play 
a role in normal gametogenesis (Mohan et al., 2011). DNMT1p primarily exists in 
pachytene spermatocytes, but a definitive role is yet to be elucidated.  
6 
 
1.2.1.2. DNMT3 
The DNMT3 family has three members, DNMT3A, DNMT3B and DNMT3L. 
DNMT3A and DNMT3B are considered to be de novo methyl-transferases and may 
play a role in methylating unmethylated cytosines to establish the pattern of DNA 
methylation in early development (Okano et al., 1999). There is some evidence that 
DNMT3A/B have no preference for hemimethylated DNA over unmethylated substrate, 
but it was recently shown that Dnmt3a and Dnmt3b are also involved in the 
maintenance of DNA methylation (Arand et al., 2012; Feng et al., 2010). Their 
contribution to de novo and maintenance methylation activity may vary between among 
the repetitive elements of the genome (Arand et al., 2012). There are also some studies 
reporting that Dnmt3a/3b are capable of binding to nucleosomes containing methylated 
DNA (Jeong et al., 2009a; Sharma et al., 2011).  
Dnmt3a
−/−
 mice die soon after birth while Dnmt3b
−/−
 embryos fail to develop (Okano et 
al., 1999). This implies important roles for both these enzymes in establishing 
methylation patterns in during development. Dnmt3b is first detected at the time of 
blastocyst formation and Dnmt3a is expressed after E10.5 (E, embryonic day) 
(Watanebe et al., 2002). Analysis of embryonic stem cells by single and combinational 
mutation of Dnmt3A and Dnmt3B showed that they are indispensable and could 
compensate each other to some extent (Chen et al., 2003).  
DNMT3L (DNA methyltransferase 3-like) protein lacks active DNA methyltransferase 
activity and is considered to act primarily as a regulator of DNMT3A and DNMT3B 
activity (Suetake et al., 2004). The interaction between DNMT3L and DNMT3B is 
essential for normal development. Mutation of the catalytic domain of Dnmt3b impairs 
the stimulation of catalytic activity by Dnmt3L and causes some auto-immune diseases 
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(Xie et al., 2006). Interactions between the DNMT3 proteins may also affect 
gametogenesis. Dnmt3L
−/−
 caused the upregulation of Dnmt3a and Dnmt3b transcripts 
in oocytes, but not spermatozoa (Niles et al., 2011). Dnmt3L disruption did not cause a 
change in the level of global methylation, but it affected the methylation pattern of 
imprinted genes in oocytes of Dnmt3L-defect mice (Bourc'his et al., 2001). However, 
the global level of methylation was decreased both in Dnmt3a−/− and Dnmt3L−/− 
oocytes (Smallwood et al., 2011). These results indicate a role for DNMT3L in 
epigenetic regulation of gametes (Niles et al., 2011), and of some somatic cells 
(O'Doherty et al., 2011), and suggest that normal development requires the proper 
activities of DNMT3 enzymes.  
1.2.1.3. DNMT 2  
DNMT2 may act as active DNA methyltransferases (Tang et al., 2003) but is also 
capable of methylating RNA (Jurkowski et al., 2008). Dnmt2 can be involved in RNA 
processing (Thiagarajan et al., 2011), and may function in RNA-mediated epigenetic 
inheritance (Kiani et al., 2013). In cellular stress, DNMT2 appears in cytoplasm but it is 
commonly present in nucleus of differentiated human cells (Thiagarajan et al., 2011). In 
Drosophila, oxidative stress results in Dnmt2 associating with a RNA-binding protein, 
and the loss of Dnmt2 caused the sensitivity to stress (Schaefer et al., 2010).  
1.2.1.4. Methyl-CpG-binding proteins  
A major part of research in DNA methylation has focused on the identification and 
characterisation of proteins which bind to methylated cytosines of DNA. It is known 
that the phenomenon of DNA methylation does not only represent the methylation of 
cytosines (5meC) in CpG islands but also a variety of proteins binding to these 
methylated DNA. These proteins are called Methyl-CpG-binding proteins (MBPs) and 
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are involved in the regulation of gene expression by DNA methylation machinery, and 
in chromatin assembly (Fournier et al., 2011; Li, 2002). These include MeCP2, MBD1, 
MBD2, MBD3, MBD4, MBD5, MBD6, Kaiso, Kaiso-like proteins and the SRA 
domain (a domain recognising methylated CpGs) proteins (Fournier et al., 2011). A 
methyl-binding domain (MBD) is common to most MBPs, and it is able to specifically 
bind to symmetrically methylated CpG (Nan et al., 1993) as a EGFP-MBD fusion 
protein has been shown to co-localise with methylated DNA (Kobayakawa et al., 2007). 
Kaiso does not possess a recognised MBD, but still can recognise the methylated 
regions (Prokhortchouk et al., 2001). Kaiso-like proteins and SRA domain proteins also 
lack a MBD (Fournier et al., 2011). MBD5 and MBD6 integrate into methylated 
heterochromatin by their MBD, but interestingly do not bind to some methylated 
sequences of DNA in human (Laget et al., 2010).  
The binding preference of the various MBPs for 5meC over unmethylated cytosines 
differs. MBD1 has the highest specificity for 5meC (93-fold), followed by MBD2 (35-
fold), MBD4 (11-fold) and MeCP2 (8-fold) (Badran et al., 2011). This makes MBD1 a 
useful tool for detecting 5meC and it has been used as an alternative measure of global 
5meC (Morita et al., 2012; Zhang et al., 2012a). There are alternative splice variants 
MBD1 (Fujita et al., 2000; Fujita et al., 1999). These share a common N-terminal and 
C-terminal, but differ in at the zinc finger domains  (Fujita et al., 2000; Fujita et al., 
1999). These isoforms, such MBD1v1 and MBD1v2, can be involved in the regulation 
of gene expression in unmethylated promoters (Fujita et al., 2000; Fujita et al., 1999), 
and can be involved in transcriptional silencing mediated by DNA methylation in 
euchromatic regions (Fujita et al., 1999).  
The differential binding affinity MBPs for 5meC may indicate differing roles of these 
proteins. For instance, the methylation-independent recruitment of MeCP2 to chromatin 
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assembly regions (Georgel et al., 2003) may be facilitated by the lower affinity of this 
MBP for 5meC (Badran et al., 2011), yet MeCP2 is implicated in recruiting histone 
deacetylases (HDACs) to methylated regions of DNA (Jones et al., 1998). No 
significant binding of MBD3 to 5meC (Badran et al., 2011) confirms earlier finding that 
MBD3 did not bind the methylated CpG nucleotides. MBD2 and MBD4 show selective 
binding preference for hemi-methylated CpGs (Hendrich and Bird, 1998) and are 
implicated in DNA methylation of satellite DNA (Li, 2002).  
The roles of MBD5 and MBD6 are relatively less understood, and found highly 
expressed in some tissues, including brain and testis (Laget et al., 2010). It is possible 
that MBD5 and MBD6 may contribute to the unique epigenetic regulation of some 
tissue-specific transcription. 
The range and diversity of actions of the MBPs shows that 5meC provides important 
topological information to DNA, provide docking sites for proteins capable of many 
important changes in chromatin structure and function. The detail of these roles and 
their regulation requires much further investigation.  
1.2.2. The functions of DNA methylation  
One important role for DNA methylation is hypothesised to be in the transcriptional 
regulation of gene expression (Hajkova, 2010; Morgan et al., 2005).  
1.2.2.1. DNA methylation in fertilisation and early embryogenesis 
A ‘classical model’ of epigenetic reprogramming during embryo development holds 
that genome-wide modification DNA methylation to the paternally and maternally-
inherited genomes occurs soon after fertilisation. This model has dominated thinking in 
the field for the last few decades. The paternal genome is reported to be rapidly 
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demethylated prior to the first round of DNA replication in the mouse (Morgan et al., 
2005; Oswald et al., 2000; Yamazaki et al., 2007) and rabbit zygote (Silva et al., 2011). 
By contrast methylation levels of the maternally-derived genome is reported to more 
gradually decline over several subsequent cell-cycles (Morgan et al., 2005; Oswald et 
al., 2000; Silva et al., 2011; Yamazaki et al., 2007). This model has been developed 
largely on the basis of immunolocalisation of 5meC in the embryo, combined with base-
level analysis by bisulfite conversion of a relatively small number of CpGs.   
A recent re-analysis of this evidence finds that using conventional methods 
immunolocalisation there a progressive loss 5meC staining in both paternal and 
maternal pronuclei occurred during zygotic maturation (Li and O'Neill, 2012). It was 
found, however, that this reduction occurred as a result of changes in the level of 
antigenic masking of 5meC (Li and O'Neill, 2012). Changing to the epitope retrieval 
method to include a brief period of tryptic digestion recovered the antigen and showed 
that there was no reduction in the level of 5meC during zygotic maturation. Staining of 
MBD1 protein (used as a proxy measure for 5meC) confirmed the persistence of 5meC 
throughout early development. It was also shown that previous reports of asymmetric 
loss of 5meC was in fact accounted for by asymmetric changes in the levels of antigen 
masking resulting from embryo culture or fertilisation of embryos in vitro (Li and 
O'Neill, 2012).  
The persistence of 5meC over early stages of development was subsequently confirmed 
(Smith et al., 2012) (using reduced representation bisulfite sequencing) of around 5% of 
the CpGs in the embryo genome. This study showed that the methylation of the 
paternally and maternally-derived genomes in the zygote had broadly similar overall 
levels of methylation, rather than a grossly lower level in male pronucleus as predicted 
by past models. The study also showed that methylation levels persisted over the first 
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several cell-cycles and then declined in the cells of the inner cell mass. These new 
results call into question past efforts to identify an active demethylase that have used the 
supposed active demethylation of the paternally-inherited genome as the model for 
analysis.  
1.2.2.2. DNA methylation in X chromosome inactivation 
DNA methylation is involved in the regulation of X chromosome inactivation during 
preimplantation development. X chromosome inactivation occurs in the cells of inner 
cell mass (ICM) of the female genome at E3.5 (E, Embryonic Day) to balance X-related 
genes (Senner et al., 2011). During oogenesis, Xist gene is only expressed in inactive X 
chromosome of the female genome and its expression is regulated by DNA methylation 
(Kim et al., 2009a; Orishchenko et al., 2012). The methylation pattern of XIST gene 
however has been found to be different between spermatogenic cells suggesting its 
possible role in epigenetic reprogramming during spermatogenesis (Nishimura et al., 
2012).  
1.2.2.3. DNA methylation in genomic imprinting 
 
DNA methylation plays a role in genomic imprinting during germ-line development. 
Imprinting is a process that causes parent-of-origin dependent mono-allelic gene 
silencing (Wolf, 2013). Imprinted genes such H19, IGF2 and IGF2R are regulated by 
allele-specific expression and the variation in H19 imprinting by DNA methylation may 
function in early programming and development (Buckberry et al., 2012). Differentially 
methylated regions (DMRs) are genomic regions with different methylation patterns 
between male and female alleles in the same cell, and DMRs are involved in genomic 
imprinting (Sun et al., 2012; Yagi et al., 2008). The methylation pattern of oocyte-based 
DMRs is maintained in the early embryo, but is progressively lost during cell 
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specification, and it is finally loss in somatic cells (Smith et al., 2012). However, sperm-
based DMRs are methylated after blastocyst stage (Smith et al., 2012). These studies 
suggest a role of DNA methylation in the establishment and/or maintenance of parental-
derived genomic imprinting.  
1.2.2.4. DNA methylation in the regulation of gene activity 
DNA methylation of the regulatory regions of loci can result in gene transcription with 
cellular differentiation. For example, pluripotency genes, OCT4, SOX2, KLF4 and 
cMYC were hypomethylated in human induced pluripotent stem cells derived from 
pancreatic beta cells (BiPSCs) whereas beta cell-specific genes (such INSULIN and 
PDX1) were hypermethylated (Bar-Nur et al., 2011). Hypomethylation pattern of beta 
cell-specific genes is maintained in BiPSCs, whereas they are methylated in fibroblasts, 
iPSCs (induced pluripotent stem cells) and ESCs (embryonic stem cells) (Bar-Nur et al., 
2011).  
Another example is the observation of global changes in the methylation pattern in 
human hematopoietic progenitor cells during differentiation (Bocker et al., 2011). 
Myeloid progenitor cells had similar DNA methylation pattern, whereas differentiated 
granulocytes and monocytes were relatively hypomethylated (Bocker et al., 2011).  
Gene-specific changes in methylation have been described in during osteoblast 
differentiation, an osteoblast-specific gene, ROR2, was hypermethylated on days 4 and 
8 of differentiation, but became hypomethylated by days 12, 16 and 20 in osteoblast 
cells, whereas methylation was maintained in mesenchymal cells (Tarfiei et al., 2011). 
DNA methylation can also regulate the expression of tissue-specific genes i.e. the 
promoter of ITGAL gene, an integrin (CD11a) coding gene, is methylated in fibroblast 
cells, but not in T cells (Lu et al., 2002).  
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1.2.3. Abnormal methylation  
Defects in DNA methylation and its associated regulatory proteins have been associated 
with some genetic diseases. Immunodeficiency, Centromere instability and Facial 
anomalies syndrome (ICF syndrome)  is caused by mutations to DNMT3B (Jin et al., 
2008a). Rett syndrome (an autism spectrum disorder) is caused by mutations to MeCP2 
(Goffin et al., 2012). Responsible mutations in the MECP2 gene include missense 
mutations at the codon for threonine 158, converting it into methionine (T158M) or 
alanine (T158A). The resulting MeCP2 protein lacks the methyl-binding activity 
(Goffin et al., 2012).  
The changes in global or gene-specific CpG methylation and in DNA methylation-
related proteins have been also reported in association with oncogenesis. Histone and 
non-histone proteins are also involved in these changes (Ting et al., 2006). Methylation 
of regulatory regions of some tumour suppressor genes has been reported, and this may 
inactivate gene expression by blocking the binding of transcription factors to the 
promoter regions (Acharyya et al., 2010; Deaton and Bird, 2011; Hagiwara et al., 2012; 
Liu et al., 2009). The resulting loss of tumour suppressor function can contribute to the 
oncogenic transformation. Examples of this include hRAB37 (responsible in membrane 
trafficking and cytoskeletal organisation) (Wu et al., 2009), CDH1 (involved in cell-to-
cell adhesion) (Kiss et al., 2013; Marsit et al., 2008), MLH1 and MSH2 (DNA repair 
genes) (Simpkins et al., 1999), DCR2 (a regulator of G1/S transition), P16 (involved in 
G1 control), RARB (involved in transcriptional repression), and RASSF1A (involved in 
cell-cycle arrest) genes (Kiss et al., 2013). 
Methylation pattern of tumour suppressor genes can vary (i) within and (ii) between the 
some types of cancers. For instance, (i) the promoter methylation pattern of tumour 
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suppressor genes (E-Cad, RARß, MGMT, hMLH1, DAPK, P16INK4a, RASSF1A, 
APC1A and FHIT) differed from sub-types of thymic epithelial tumours (TETs) and the 
stage of tumourogenesis (Chen et al., 2009). Promoter methylation of these genes 
occurred with global loss of methylation in early stages of TETs, followed by increased 
DNMT1, 3A/3B levels in further stages (Chen et al., 2009). DAPK (Death Associated 
Protein Kinase), an apoptosis gene, was commonly methylated in multiple myeloma 
(MM), but increased methylation was not the case for tumour suppressor genes, p14 and 
Apaf-1 (Chim et al., 2007). The differences in methylation profiles between the similar 
types of cancers (ii) were observed in such TLE1 gene (a mediator of growth inhibition). 
The promoter of TLE1 was methylated in hematologic malignancies, including acute 
myeloid leukaemia, non-Hodgkin’s lymphoma, chronic myeloid leukaemia, and diffuse 
large B cell lymphomas, whereas it was demethylated in acute lymphocytic leukaemia 
(Fraga et al., 2008).  
Deregulation of DNA methylation can also induce deletions in imprinted loci and the 
disruption of imprinting (Kisseljova and Kisseljov, 2005). Hypermethylation at 
differentially methylated regions of H19 and IGF2 has been associated with the loss of 
heterozygosity (LOH) in yolk sac tumour formation (Furukawa et al., 2009). 
These all suggest the role of DNA methylation in the gene regulation for normal 
development in mammals since some alterations of DNA methylation can cause a wide 
range of abnormalities.  
1.2.4. Modifications of 5-methyl-cytosine  
Recent studies have focussed on the variations in the structure of 5-methylcytosine. 
TET1 (ten eleven translocation-1, an enzyme from a group of 2-oxoglutarate (2OG)- 
and Fe(II)-dependent dioxygenases) enzyme has been identified to catalyse the 
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conversion of 5meC to 5-hydroxymethylcytosine (5hmC) in human (Tahiliani et al., 
2009).  5hmC was first discovered in bacteriophages (Wyatt and Cohen, 1952), and 
recently found in mammalian neurons (Kriaucionis and Heintz, 2009). 5hmC is 
associated with transcriptional repression in the gene promoters (Robertson et al., 
2011). The role of other members of Tet family (Tet2, Tet3) in this conversion has been 
further determined in mouse (Ito et al., 2010).  
The pattern of 5hmC showed some tissue specificity. CCGG sequences (recognised by 
the restriction enzymes MspI and HpaII) in genomic DNA from embryonic stem cells 
and brain showed high rates of 5hmC, however; the same sequences were demethylated 
at a much lower level in heart and spleen cells (Kinney et al., 2011). Central nervous 
system tissues showed the highest level of 5hmC, but the amount of 5meC did not differ 
in some mammalian tissues (central nervous system, kidney, bladder, heart, muscle, 
lung, spleen and testes) (Globisch et al., 2010).  
The function of 5hmC in differentiation has been reported (Kinney et al., 2011). The 
level of both 5hmC and Tet1 decreased during embryoid body differentiation in mouse, 
whereas the level of both Dnmt3a and Dnmt3b proteins increased (Kinney et al., 2011). 
However, there was no change in the expression of Dnmt1 (Kinney et al., 2011). While 
the level of 5hmC decreased during the differentiation of embryonic stem cells, the level 
of 5meC increased (Kinney et al., 2011). The regulation of 5hmC by Tet1 and Tet2 
enzymes was shown in mouse embryonic stem cells (ESCs) and induced pluripotent 
stem cells (iPSCs) (Koh et al., 2011). Oct4 depletion (Oct4 encodes a transcription 
factor in pluripotency) correlated with decrease in Tet1 and Tet2 mRNA (Koh et al., 
2011). Tet1 is strongly associated with its target pluripotency genes, such as Sox2, Klf4 
and Oct4, in embryonic stem cells, however; expressions of these genes were not 
changed after Tet1 depletion (Xu et al., 2011). Interestingly, Tet1 depletion caused  
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decrease in the transcripts of some genes involved in neurogenesis (Xu et al., 2011). It 
can suggest that Tet1 appears to be an important regulator for transcription status of 
neurogenesis genes, but not of pluripotency genes. Taken together, 5hmC, modified 
from 5meC by Tet enzymes, is associated with transcriptional silencing and can have 
some role in lineage-specific expression of some genes. However, 5hmC is reported to 
accumulate within euchromatic regions but not within heterochromatin. This may 
indicate an association of this modification with increased gene transcription (Ficz et al., 
2011; Kubiura et al., 2012).  
The action of the TET enzymes on 5hmC can cause its further conversion to 5-
carboxylcytosine( 5caC) or  5-formylcytosine (5fC). These TET-mediated derivatives of 
5meC have been hypothesised to be intermediates in a 5meC DNA demethylation 
pathway (Alioui et al., 2012; Guo et al., 2011; Pfaffeneder et al., 2011). 5hmC can also 
be converted to 5hmU (5-hydroxymethyluracil) by AID/APOBEC enzymes, and this 
may be involved in demethylation through DNA repair. The possible roles of these 
5meC forms are detailed in section 1.3.1.2.  
1.3. DNA demethylation 
1.3.1. The machinery and function of DNA demethylation  
1.3.1.1. Passive demethylation 
Passive demethylation refers to the failure of conservative methylation of 
hemimethylated CpGs resulting from DNA replication (Morgan et al., 2005; Patra et al., 
2008). DNMT1 interacts with PCNA (proliferating cell nuclear antigen, a protein 
involved in genome organisation) during DNA replication to maintain the mitotic 
inheritance of the methylation pattern (Schermelleh et al., 2007; Wolffe et al., 1999).  
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In normal circumstances, DNMT activity completes the symmetrical methylation of the 
hemimethylated DNA that results from DNA replication (Wolffe et al., 1999) (Figure 
1-2A). Passive DNA demethylation during replication can occur if DNMT activity is 
inhibited either by nucleoprotein complexes (Figure 1-2B) (Hsieh, 1999; Matsuo et al., 
1998) or histone acetylation (Figure 1-2C) (Selker, 1998). Nucleoprotein complexes 
basically contain DNA and proteins. Some transcription factors, such as Sp1 and Gal4 
in Xenopus (Matsuo et al., 1998), and EBNA-1 in human (Hsieh, 1999) can induce 
demethylation during DNA replication. Histone acetylation was also associated with 
demethylation in fungus (Selker, 1998). However, CpGs can be targeted by DNMT1 
even if DNA is wrapped with nucleosomes (Okuwaki and Verreault, 2004).  
DNMT1 is capable of interacting both with non-replicating and replicating chromatin 
regardless of DNA methylation status, suggesting that DNMT1 may also function 
independent on DNA replication (Shimamura and Ishikawa, 2008). DNMT1 associates 
with histone methylation in chromatin during DNA replication (Esteve et al., 2006), and 
also recruits to the chromatin during G2 and M phases of cell-cycle (Easwaran et al., 
2004).  
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Figure 1-2. Passive Demethylation in DNA replication.  
In DNA replication, two methylated DNA strands of the genome are separated into 
daughter chromatids and form hemimethylated DNA strands, followed by either that (A) 
in normal circumstances, DNMT completes the symmetric methylation, and therefore 
maintains DNA methylation pattern of the original strand, or DNMT activity is blocked 
by either (B) regulatory nucleoprotein complexes or (C) histone acetylation, resulting in 
the loss of methylation. Adapted from Wolffe et al. (1999). 
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1.3.1.2. Active demethylation  
Evidence in plants implicates active DNA demethylation by a 5meC-specific DNA 
glycosylase enzyme acting within the base-excision repair pathway (BER). The 
possibility of similar DNA demethylation mechanism in animals has been proposed 
(Barreto et al., 2007; Cortellino et al., 2011; Rai et al., 2008; Zhu, 2009).  
Alternative hypotheses for active demethylation include: (i) the conversion of 5meC to 
thymine followed by a putative DNA glycosylase activity in the BER pathway (indirect 
demethylation) (Wolffe et al., 1999): or (ii) a reaction of the removal of 5meC catalysed 
by a putative DNA demethylase (direct demethylation) (Jost, 1993; Jost et al., 1995; 
Wolffe et al., 1999). Some findings support the presence of a 5-methylcytosine DNA 
glycosylase activity in demethylation in some plants such as Arabidopsis (Mok et al., 
2010) and rice (La et al., 2011), and in some animals such as chicken (Jost et al., 1995; 
Zhu et al., 2000b), bird (Zhu et al., 2000a) and human (Zhu et al., 2001).  
Recent discoveries suggest a role for 5hmC and TET proteins in active demethylation, 
the current model for active demethylation has been hypothesised to be mediated by 
5hmC (Guo et al., 2011; Tahiliani et al., 2009). This model suggests that demethylation 
occur either by: (i) deamination of 5hmC to 5hmU by AID/APOBECs (a family of 
cytidine deaminases) (AID-Activation Induced Deaminase) followed by the excision of 
5hmU by glycosylases (such as TDG, Thymine DNA Glycosylase) and replacement 
with cytosine through the BER pathway (Figure 1-3A) (Cortazar et al., 2011; Cortellino 
et al., 2011; Guo et al., 2011): or (ii) oxidation of 5hmC to 5fC and 5caC followed by 
replacement as described for 5hmC (above) by the BER pathway (Figure 1-3B) (He et 
al., 2011; Ito et al., 2011; Maiti and Drohat, 2011). Other possible mechanism may 
include conversion of 5fC or 5caC to cytosine catalysed by a decarboxylase enzyme (Ito 
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et al., 2011) (Figure 1-3). The structures of metabolites of 5meC are shown in Figure 
1-4.  
 
 
 
Figure 1-3. Current model for active DNA demethylation.  
5hmC-mediated demethylation is hypothesised to occur either by (A, green arrows) 
deamination of 5hmC to 5hmU by AID/APOBECs, then the excision of 5hmU by 
possible glycosylases (such as TDG, Thymine DNA Glycosylase or MBD4) and 
replacement of cytosines through the BER pathway, or (B, blue arrows) oxidation of 
5hmC to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) followed by cytosine 
replacement the BER pathway. Black arrows indicate a possible pathway of 
demethylation through 5fC and 5caC by a decarboxylase.  
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Figure 1-4. Structures of modified bases from 5-methylcytosine.  
5meC (5-methylcytosine), 5hmC (5-hydoxymethylcytosine), 5hmU (5-
hydroxymethyluracil), 5fC (5-formylcytosine) and 5caC (5-carboxylcytosine) are 
shown. Arrows represent the conversions. 
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Evidence in support of a role of this pathway includes the observation that removal of 
5hmC is blocked by inhibition of two components of the BER pathway: poly (ADP-
ribose) polymerases (PARPs) and apurinic/apurimidinic endonuclease APE1 enzymes 
(Guo et al., 2011). AID overexpression resulted in the decreased level of 5hmC 
demethylation, and 5meC demethylation was increased by co-expression of AID and 
TET1 in human embryonic kidney cells (HEK239 cells) (Guo et al., 2011). These 
findings support a role for conversion of 5meC to 5hmC by TET followed by the 
deamination of 5hmC to 5hmU by AID/APOBEC. Therefore, this deamination could be 
a signal for removal of methylated cytosines in base-excision repair. Furthermore, the 
conversion of 5meC to 5hmC was induced by transforming-growth factor-β (TGF-β) (a 
cytokine, involved in cell proliferation, differentiation, adhesion and migration) at the 
p15
ink4b
 promoter (a tumour suppressor gene, cyclin-dependent kinase, cdk inhibitor) 
(Thillainadesan et al., 2012). In human, knockdown of TDG or MBD4 causes the 
inhibition of TGF-β-dependent p15 demethylation, resulting in a increase in the level of 
5hmC (Thillainadesan et al., 2012). However, the effect of knockdown of AID or 
APOBEC2 on 5hmC accumulation was not as much as the effect of knockdown of TDG 
or MBD4 (Thillainadesan et al., 2012). It can conclude that DNA glycosylase activity 
(particular by TDG or MBD4) plays a role in TGF-β-dependent p15 demethylation, and 
that the levels of 5meC and 5hmC reduce at the promoter of p15 in the cellular response 
to TGF-β treatment.  
TET proteins can also catalyse the oxidation of 5meC to 5-formylcytosine (5fC) and 5-
carboxylcytosine (5caC) (Ito et al., 2011). The existence of possible demethylation 
intermediates, 5caC, 5hmC, 5hmU and 5fC, in genomic DNA from mammalian tissues 
was examined by HPLC-MS to assess whether 5hmC was involved in an oxidative 
demethylation, but these intermediates were not detectable at significant levels 
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(Globisch et al., 2010). This suggests either that (i) these intermediates may not 
accumulate or that (ii) the proposed oxidative demethylation may not occur (Globisch et 
al., 2010). However, these oxidised forms of 5meC were detected in the genomic DNA 
of mouse embryonic stem cells and organs using HPLC and mass spectrometry (Ito et 
al., 2011; Pfaffeneder et al., 2011). 
Human thymine-DNA glycosylase is able to excise 5-formylcytosine (5fC) and 5-
carboxylcytosine (5caC) from DNA (Maiti and Drohat, 2011; Zhang et al., 2012b). 
Another glycosylase, SMUG1, could not excise either 5fC (Masaoka et al., 2003) or 
5caC from DNA (He et al., 2011), but was able to excise 5hmU (Kemmerich et al., 
2012). MBD4 has a function in removing thymine or uracil from the G-T or G-U 
mismatches in CpG islands of the mouse genome, and it has been defined as “a 
mismatch-specific T/U glycosylase” (Hendrich et al., 1999). The glycosylase activity of 
Mbd4 enzyme was confirmed in zebrafish embryos (Rai et al., 2008). However, MBD4 
is not able to remove carboxyl group from 5caC (He et al., 2011) and it does not have 
endonuclease activity (Hendrich et al., 1999). The association of MBD4 with BER 
factors on the CpG-rich regions of CYP27B1 (cytochrome p450 27B1, involved in 
vitamin D metabolism) gene promoter was induced by demethylation after parathyroid 
hormone treatment (Kim et al., 2009b). These studies suggest that a glycosylase activity 
may be involved in active DNA demethylation through DNA repair pathway. It should 
be considered that there can be a potential decarboxylase enzyme converting 5caC to C, 
yet it has not been identified.  
Some proteins involving in differentiation or in DNA repair have been found to 
associate with active demethylation. For instance, Rnf4 gene (encoding a RING finger 
protein 4, a SUMO-dependent ubiquitin E3-ligase) deficiency caused embryonic 
lethality with high methylation in the genomic DNA, and Rnf4 protein was found to 
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interact with Tdg and Ape1 (Hu et al., 2010). It suggests the possible role of Rnf4 in 
embryonic development and in DNA demethylation through BER pathway. Growth 
arrested DNA-damage-inducible protein 45 alpha (Gadd45a) involved in DNA repair, 
genome stability and the inhibition of cell growth, was found to participate in active 
demethylation through the direct interaction with DNA repair endonuclease XPG in 
Xenopus (Barreto et al., 2007). The global demethylation was also regulated by Gadd45 
in the cellular response to UV treatment (Barreto et al., 2007). However, Jin et al. 
showed no function of Gadd45 in DNA demethylation, and no association with Xpg 
repair enzyme in the mouse (Jin et al., 2008b). Nevertheless, the Gadd45 protein family 
participate in demethylation involving Apobec deaminase and an Mbd4-related G-T 
glycosylase in zebrafish embryos (Rai et al., 2008). Gadd45a depletion caused 
hypermethylation of osteogenic lineage specific genes, including Dlx5, Runx2, Bglap 
and Osterix, but it did not change the expression of Hoax10 and Col1 genes (Zhang et 
al., 2011b). These reports indicate that the loss of methylation affects gene expression 
and that there are a range of proteins possibly involving in DNA demethylation, 
however; these proteins have not been completely identified yet. Current evidence 
implicates mechanisms within the DNA repair pathway for base-level active 
remodelling of the cytosine methylation. 
1.3.2. The functions of DNA demethylation  
Demethylation of some alleles occurs in early embryogenesis and primordial germ cell 
development and may contribute to their pluripotent state. For instance, the CpGs of 
pluripotency genes, POU5F1 and NANOG, are demethylated in pluripotent cells and 
become hypermethylated upon differentiation (Nazor et al., 2012). Furthermore the 
expression of XIST was lost in the majority of pluripotent clones, and the different 
methylation patterns of X chromosome in the female pluripotent cells are dependent on 
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the level of XIST expression (Nazor et al., 2012). Tissue-specific gene expression in 
differentiated cells is also controlled by DNA demethylation. For example, DMRs of 
liver-specific genes, Hnf1a and Hnf4a, were detected highly demethylated in mouse 
liver, compared to cerebrum, kidney and spleen by bisulfite sequencing and microarray 
analyses (Yagi et al., 2008).  
Methylation also has important roles at repetitive elements, such as LINE 1 (long 
interspersed nuclear element-1), ETn, ALU sequences, satellite DNA and endogenous 
retroviruses (i.e. IAP, intracisternal A particle). These elements comprise almost half 
content of the human genome, most of which are derived from the activity of 
transposable elements, and their methylation profiles are commonly detected using 
bisulfite-based methods (Wicker et al., 2007). These elements, i.e. LINE 1 and satellite 
DNA, are known to influence global methylation in normal cells, but they are found 
demethylated in some cancers and genetic abnormalities and therefore increase the 
genomic instability (Lu et al., 2006; Verma et al., 2004; Zhang et al., 2011a). IAP is a 
methylation-dependent retrovirus region of the genome and its upregulation induces 
p53-dependent cell death in Dnmt1-deficient mouse fibroblasts (Grusby et al., 2001).  
Methylation of these repetitive DNA elements is a dynamic process and the changes in 
their DNA methylation pattern occur in development and germ cell reprogramming. 
Line 1 and Etn elements are hypermethylated in sperm, oocytes and late zygotes (PN4-
PN5 - PN: Pronuclear stage) (Iqbal et al., 2011). In further development the highest 
level of methylation of such IAP, Line 1 and minor satellite DNA was observed at E12.5 
while many single-copy genes lost methylation. These elements are then demethylated 
in male germ cells between E15.5 and E17.5 but not in female germ cells (Lees-
Murdock et al., 2003).  
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Global DNA demethylation of the whole genome occurring in early embryogenesis has 
been mostly reported and is therefore thought to have a role in development. For 
instance, using immunofluorescence the signal of 5meC staining was found 
progressively lost in the paternal genome as the zygote developed but 5hmC was 
present in the paternal genome (Iqbal et al., 2011). The loss of 5meC was also observed 
(after acidic denaturation with 4N HCl) in the paternal pronucleus from PN2 to PN3, 
but not in the maternal pronucleus at PN1-5, and 5hmC (after HCl) accumulated while 
5meC was lost (Hatanaka et al., 2013). The appearance of 5hmC along with a reduction 
of 5mC in the paternal pronucleus has been also shown through the similar method of 
fluorescence microscopy (Inoue and Zhang, 2011; Iqbal et al., 2011; Wossidlo et al., 
2011). These reports would indicate a possible role of demethylation during 
embryogenesis. However, these findings are now contradictory since trypsin after acid 
increased the antigenicity for 5meC epitope and revealed a persistence staining of 5meC 
as discussed in previous sections. This highlights the need for rigorous validation of the 
methods of immuno-localization of 5meC, so as to prevent artefactual interpretation of 
results. Therefore the proposed role of global demethylation of DNA in early 
embryogenesis is likely due to the artefact of measurement.  
1.4. Measurement of DNA methylation 
The analysis of CpG methylation can be performed at multiple levels: (a) the total 
content of methylated cytosines in the genome, (b) the level of methylation at individual 
CpG dinucleotides, (c) the symmetry of methylation at individual CpG dinucleotides, 
and (d) the landscape profile of methylation across the genome (Laird, 2003). The 
measurement of CpG methylation can be classified into two main groups according to 
the aim: (i) site-specific, and (ii) global methylation (Fraga and Esteller, 2002).  
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(i) The site-specific analysis is to investigate the base-level methylation patterns of 
specific genes or loci in the genome. The site or locus-specific methylation can be 
detected by a range of methods, including methylation-specific PCR after bisulfite 
conversion (Herman et al., 1996; Karouzakis et al., 2009), combined bisulfite and 
restriction analysis (COBRA) (Xiong and Laird, 1997), methylation-specific PCR of 
repetitive elements (Yang et al., 2004) and micro-array based techniques (Bibikova et 
al., 2011; Chowdhury et al., 2011). 
 
(ii) Global methylation can be detected by methods including HPLC (high 
performance liquid chromatography) (Ehrlich et al., 1982; Kuo et al., 1980), HPCE 
(high-performance capillary electrophoresis) (Li et al., 2009), mass spectrometry 
(Annan et al., 1989; Coolen et al., 2007), anti-5meC immunological techniques (Brown 
et al., 2008; Habib et al., 1999; Karouzakis et al., 2009; Piyathilake et al., 2004; 
Schneider and Fagagna, 2012), and genome mapping with micro-arrays (Bar-Nur et al., 
2011; Bocker et al., 2011; Walker et al., 2011).  
Most of the genome-wide (e.g. infinium array) and site-specific analysis of 5meC (e.g. 
methylation-specific PCR) are based on bisulfite conversion of unmethylated cytosines 
to uracils, but methylated cytosines are not modified, allowing sequencing to  
distinguish between methylated and unmethylated cytosines (Bibikova et al., 2009; 
Herman et al., 1996). However, it has recently been found that this technique does not 
only convert 5meC but also acts on 5hmC, 5caC and 5fmC. Thus, bisulfite conversion 
based methods provide a measure of the net level of all covalent modifications of 
cytosine, not just a measure of 5meC.  (Huang et al., 2010; Nestor et al., 2010). After 
bisulfite treatment, 5meC is not modified, whereas 5hmC is converted to 5-
methylenesulfonate (CMS). But CMS is not deaminated, and 5hmCs are therefore 
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recognised as 5meC (Huang et al., 2010). Further studies now show that 
methylcytosine-sensitive enzymes, HpaII, PstI, HpyCH4IV, HhaI and HaeII, were also 
not able to discriminate between 5meC and 5hmC at the human BRCA1 CpG island 
promoter (Nestor et al., 2010). These results show that methods using bisulfite 
conversion and/or methylation-specific restriction do not selectively detect 5meC. These 
methodological limitations indicate that considerable caution is required in the 
interpretation of past ‘methylome’ maps using this techniques.  
There have been a number of recent modifications to these methods in an attempt to 
circumvent this lack of specificity. A new method allows the specific sequencing of 
5hmC by selective oxidations of individual DNA bases has been recently reported 
(Schüler and Miller, 2012). Specific oxidation of 5hmC to 5fC is achieved by treatment 
with potassium perruthenate, and the resulting 5fC is then converted to uracil using the 
bisulfite conversion reaction (Booth et al., 2012). Huang et al. developed “sodium 
bisulfite treatment” for conversion of 5hmC to CMS (cytosine-5-methylenesulfonate) 
and this new approach specifically revealed the genome-scale prolife of 5hmC (Huang 
et al., 2012). Yu et al. developed TET-assisted bisulfite sequencing (TAB-Seq), which 
combines traditional bisulfite sequencing with methyl-Seq which includes additional 
steps for glucosylation and TET oxidation of genomic DNA, thus it distinguishes 5meC 
from 5hmC (Yu et al., 2012a; Yu et al., 2012b). These approaches for bisulfite based-
methods improve selectivity but come at a cost of limited sensitivity.  
An advantage of immunologically based assays with specific antibodies such as DNA 
immunoprecipitation with anti-5meC (MeDIP, methylated DNA immunoprecipitation 
or immunolocalisation), is that it allows highly selective recognition of 5meC, and the 
other cytosine modifications (Jin et al., 2010; Nestor et al., 2010). Antibody-based 
techniques for cell or tissue samples necessarily include “antigen retrieval” procedures 
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for the specific staining of the antigen of interest. These aim to increase antigenicity and 
can consist of treatments such as acid (i.e. HCl, citric acid, formic acid) (Gustafsson et 
al., 2010; Kitamoto et al., 1987), enzyme (i.e. trypsin) (Li and O'Neill, 2012) or heat-
induced retrieval (i.e. pre-heated citrate, tris or EDTA buffers) for unmasking of 
epitopes (Yamashita, 2007). The choice of retrieval approach depends on the nature of 
antigen and its location within the cell/tissue (nuclear, cytoplasm or at cell surface). For 
instance, acidic treatment can degrade proteins so that no acidic denaturation was 
applied for the immunostaining of some nuclear proteins such MBD1 and 
heterochromatin protein-1-α (HP1-α) in differentiated human cells (Fujita et al., 1999; 
Fujita et al., 2003), but MBD1 staining was detectable in mouse zygotes after acid (Li 
and O'Neill, 2012). However, trypsin treatment following acid caused undetectable 
immunostaining of MBD1 epitope (Li and O'Neill, 2012).  
To date, the 5meC epitope has been commonly detected using immunostaining with a 
standard HCl treatment (2-4N) (Ciccarone et al., 2012; Deshmukh et al., 2011; Salvaing 
et al., 2012; Santos et al., 2010). But a combination of acid and trypsin treatment 
revealed the increased level of 5meC staining (Li and O'Neill, 2012). This provides the 
further unmasking of the 5meC antigen, and suggests the revisiting the antigenic 
retrieval methods for staining of 5meC epitope.  
Changes in the level of global methylation have been frequently reported in a wide 
range of malignancies. These alterations are commonly investigated using bisulfite-
based methods. For instance, global demethylation was reported such in hepatocellular 
carcinoma (Zhang et al., 2012c) and in breast cancer (Hon et al., 2012). Analysis the 
level of staining intensity of 5meC epitope is another method for the detection of 
methylation changes in cancer. For instance, microscopic analyses revealed that global 
demethylation status can differ from subgroups of cancers, such as testicular germ cell 
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tumours (Netto et al., 2008). Demethylation was detected in intratubular germ cell 
neoplasia and seminoma, but not in non-seminomatous germ cells tumours (Netto et al., 
2008). These methylation alterations associated with carcinogenesis suggest the 
importance of reliable detection of DNA methylation so that provide more 
understanding for the regulation of DNA methylation and lead to improve certain 
therapeutic approaches.  
1.5. DNA methylation and chromatin organisation 
The chromatin structure of the mammalian genome is a complex of DNA, a substantial 
RNA component and proteins including histone and non-histone proteins (Black and 
Whetstine, 2011; Kouzarides, 2007). Epigenetic modifications to chromatin play a role 
in the gene regulation during embryogenesis and development. With the increasing 
evidence and interest in three-dimensional structure of chromatin, chromatin 
remodelling by the modification on histone, non-histone proteins and DNA may be an 
important component of cell’s epigenetic programme. The dynamic nature of chromatin 
conformation is proposed to be associated with these modifications (Chantalat et al., 
2011; Munari et al., 2012; Papazvan et al., 2013). Microscopy-based applications are 
frequently used methods for investigation of the nuclear localisation of the chromatin 
marks. The staining of some heterochromatin markers, H3K9me3 (trimethylation of 
lysine 9 of histone H3), 5meC (retrieved using 2M HCl pre-treatment) and HP1-β 
(heterochromatin protein 1-β), was present in preimplantation embryos, however; some 
other heterochromatin markers, H4K20me3 (trimethylation of lysine 20 of histone H4) 
and HP1-α (heterochromatin protein 1-α), were detected in embryonic stem cells (ES), 
but not in epiblast and in the inner cell mass (ICM) of the blastocyst (Wongtawan et al., 
2011). It shows that H4K20me3 and HP1-α, but not H3K9me3, 5meC and HP1-β, can 
be present in late development stages, independent on differentiation. The immune-
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detection of the level of such heterochromatin marks (a histone protein variant (nuclear 
macroH2A) and HP1-α) showed some variation in tissues and cell aging affected the 
level of staining with an increase in late passage cultures, but not in early passages of 
human fibroblasts (Kreiling et al., 2011).  
Chromatin reorganisation is also associated with DNA methylation-related proteins and 
histone modifications. DNMT1 interacts with a histone methylase, G9a, on nucleosome, 
and this interaction enhances DNA methylation during DNA replication (Esteve et al., 
2006). However, the association of DNMT1 with chromatin during or after DNA 
replication is independent on the methylation status of DNA (Shimamura and Ishikawa, 
2008). Nucleosomes at OCT4 and NANOG promoters were methylated by DNMT3B 
and DNMT3L activities, resulting in transcriptional silencing (You et al., 2011). The 
binding of DNMT3L to nucleosomes through the unmethylated lysine 4 of histone H3 
induced de novo DNA methylation (Ooi et al., 2007). The inhibition of histone 
deacetylase resulted in the changes in DNA topology from heterochromatin to 
euchromatin with the redistribution of topoisomerase II (Cowell et al., 2011).  
MBD1 positioned in heterochromatin through a protein complex including chromatin 
assembly factor 1 (CAF-1) and HP1-α in human (Reese et al., 2003). MBD1 is also 
associated with HDAC5 (histone deacetylase-5), BAHD1 (bromo adjacent homology 
domain-containing protein-1) and some transcription factors in heterochromatin-
mediated gene silencing (Bierne et al., 2009). The number of foci with MBD1 staining 
throughout the nuclei increased during embryonic stem cell differentiation 
(Kobayakawa et al., 2007). MBD2 and MeCP2 accumulated into pericentric 
heterochromatin with increased level of expression in myogenic differentiation (Brero et 
al., 2005). By contrast, MBD1 isoforms (MBD1v1, MBD1v2, MBD1v3 and MBDv4) 
were found to regulate gene expressions in euchromatic regions of human genome 
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(Fujita et al., 1999). Using immunofluorescence 5hmC has been also shown to 
accumulate in euchromatin but not in heterochromatin in mouse embryonic stem cells 
and it suggests that 5meC pre-existed in euchromatin but then converted to 5hmC by 
Tet enzymes (Kubiura et al., 2012). However, euchromatin and heterochromatin are not 
strictly separated from each other as thousands of euchromatic regions have been 
detected within large heterochromatic regions in the genome (Wen et al., 2012).  
Taken together, 5meC itself and methylation-related proteins, such as DNMTs and 
MBPs, are involved in chromatin remodelling. Histone modifications also participate to 
chromatin reorganisation. It is known that the majority of methyl groups locate into the 
nuclease digestion-resistant regions of DNA (Razin and Cedar, 1977), indicating that 
methyl groups may associate with chromatin proteins in DNA. This concludes that 
5meC may be masked by a range of proteins under some circumstances. However, the 
cross-talk between these protein complexes in chromatin dynamics still remains unclear 
in detail.  
1.6. The link between DNA methylation and DNA damage and repair 
1.6.1. DNA damage and DNA repair systems 
DNA damage can affect the pattern of DNA methylation (Chaudhry and Omaruddin, 
2012; Poage et al., 2011; Walker et al., 2011; Wermann et al., 2010) and a line of 
evidence indicates that the loss of methylation is possibly involved in DNA repair  
(Cortazar et al., 2011; Cortellino et al., 2011; Guo et al., 2011). Cellular responses to 
DNA damage are driven by a variety of DNA repair systems, and chromatin structure is 
redesigned by the interactions of proteins and DNA during repair mechanisms. DNA 
damage can result from either internal (such as alkylation, oxidation or hydrolysis) or 
external factors (such as UV, ionizing radiation, temperature and pH changes, and some 
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drugs) (Hakem, 2008). These factors may cause DNA damage, such as chromosomal 
disorganisation, genomic instability, single-strand DNA breaks (SSBs) and double-
strand DNA breaks (DSBs) (Caldecott, 2008; Watson et al., 2004). DNA damage may 
result in some heritable diseases, e.g. Spinocerebellar Ataxia with Axonal Neuropathy 1 
(SCAN1) (El-Khamisy et al., 2005), and some cancer development, such skin cancer 
induced by UV exposure (Loignon and Drobetsky, 2002; Pavey et al., 2001; Wang et 
al., 2010; You et al., 2000). UV treatment can cause single- and double-strand breaks in 
DNA (Dunkern and Kaina, 2002), and induce the phosphorylation of a histone variant 
H2A.X (γH2A.X) and the accumulation of repair-related proteins (Oh et al., 2011; 
Sustackova et al., 2012; Zhao et al., 2009). UV also caused dynamic changes in the 
nucleolus with reorganisation of nucleolar proteins, such AATF, GNL3, DDX56 and 
Ku70 (Moore et al., 2011). Another example of external agent includes doxorubicin that 
is a DNA intercalating drug used for cancer therapy. It is able to kill cancer cells 
through the cross-links in DNA. However, it has strong side effects on healthy cells, and 
may result in mutagenesis and carcinogenesis (Zhijian et al., 2009). Doxorubicin can 
cause DSBs in DNA through topoisomerase II-β inhibition (Lyu et al., 2007) or SSBs 
through free radical generation (Voest et al., 1993). 
DNA repair gene products are responsible for recognition and correction the damage. 
Repair genes function in the check-points of cell-cycle. DNA damage can be corrected 
before (Gichner and Veleminsky, 1979; Rampakakis and Zannis-Hadjopoulos, 2009) or 
after DNA replication (Otterlei et al., 1999) or during replication (Dou et al., 2010; 
Petermann et al., 2010). Damaged DNA is corrected by a variety of mechanisms in the 
cells. The DNA repair system is classified into sub-groups including the direct reversal 
pathway, base-excision repair (BER), nucleotide-excision repair (NER), mismatch 
repair (MMR), homologous recombination (HR) and non-homologous end-joining 
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(NHEJ) (Dinant et al., 2008; Gill and Fast, 2007; Hakem, 2008; Martin et al., 2008) 
(Figure 1-5A-F). Active DNA demethylation is supposed to be associated with the base-
excision repair, as discussed before.  
 
Figure 1-5.  DNA repair machinery.  
Genotoxic and cytotoxic stressors can induce single and double-strand breaks in DNA. 
DNA damage is repaired by different mechanisms. (A) The direct reversal pathway is a 
one-step mechanism of the removal methyl groups from guanines without any excision 
activity. This reaction is catalysed by O6-Methylguanine DNA Methyltransferase. (B, C, 
D) Single-strand breaks can be repaired either by mismatch repair, nucleotide-excision 
repair or base-excision repair. (E, F) Double-strand breaks can be repaired either by 
homologous or non-homologous pathways. Coloured regions (green, red, blue, orange, 
pink and purple) on the DNA strand represent the repair. Adapted from Gill and Fast 
(2007) and Hakem (2008).  
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1.6.2.  DNA (de)methylation and DNA repair 
DNA methylation machinery can be recruited as a part of the cellular response to DNA 
repair. For instance, Dnmt1, but not Dnmt3a/3b, is accumulated in UV-induced lesions 
in both mouse and human cells (Mortusewicz et al., 2005). Dnmt1 is also recruited to 
the DSBs in response to DNA damage induced by laser micro-irradiation (Ha et al., 
2011). DNMT1, MBD4 and MLH1 (a mismatch repair protein) were recruited to the 
micro-irradiated sites of nuclei (Ruzov et al., 2009). Dnmt1 was observed in 
micronuclei in doxorubicin-treated human colorectal cancer cells (Tan and Porter, 
2009). The activity of DNA methyltransferase enzymes was less sensitive to thymine 
dimers and DSBs than SSBs (Wilson and Jones, 1983). Oxidative stress induced the 
formation of a large silencing complex containing Polycomb proteins (involved in 
development and differentiation) and DNMTs (O'Hagan et al., 2011).  
The level of global methylation can alter depending on exposure time and dose of 
genotoxic stressors. For instance, hyperoxia (the excess of oxygen) caused global loss 
of methylation (detected using HpaII restriction enzyme) in lung epithelial-like A549 
cells (Panayiotidis et al., 2004). This loss of methylation was associated with the 
increase in the level of single and double-strand DNA breaks (Panayiotidis et al., 2004). 
Global methylation (detected using immunofluorescence with a standard HCl treatment) 
is reported to be reduced by treatment with genotoxic treatments of in neural stem cells 
(NSC) (Schneider and Fagagna, 2012).  
A role of the DNA repair pathways in active DNA demethylation has been reported in 
plants (Agius et al., 2006; Choi et al., 2002; Gehring et al., 2006; Gong et al., 2002), 
and is hypothesised as a component of active DNA demethylation pathways in animals 
as well (Barreto et al., 2007; Cortellino et al., 2011; Hajkova et al., 2008; Kress et al., 
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2006; Rai et al., 2008). The association of DNA demethylation with DNA strand-breaks 
was examined in cloned embryos (Wossidlo et al., 2010). Inhibition of DNA replication 
and repair-associated DNA polymerase activities resulted in pre-replicative (paternal 
only) and replication (both pronuclei)-associated enrichment of γ-H2A.X foci (Wossidlo 
et al., 2010). H2A.X is a histone variant, and its phosphorylated form (γ-H2A.X) is used 
as a biomarker for detection of DNA damage (Kuo and Yang, 2008; Mah et al., 2010; 
Marti et al., 2006; Paull et al., 2000; Redon et al., 2010; Wossidlo et al., 2010). 
Immunolocalisation revealed: (i) a maximum increase in the focal staining of γ-H2A.X 
throughout the paternal nuclei, and (ii) co-localisation of γ-H2A.X foci with PARP-1 
(Poly [ADP-ribose] polymerase-1, a component of base-excision repair pathway) in pre-
replicative early PN3 paternal pronuclei (Wossidlo et al., 2010). In this pronuclear 
stage, the signal of 5meC was decreased in the paternal pronucleus (Wossidlo et al., 
2010). It was concluded that demethylation occurred in paternal pronucleus at a 
particular stage from PN2 to mid-PN3, and was independent on DNA replication. This 
demethylation is associated with γ-H2A.X and PARP-1 (Wossidlo et al., 2010). 
Western-blot and immunofluorescence analyses showed that the level of Parp-1 
expression was high in mouse primordial germ cells when the loss of methylation 
occurred during germ line epigenetic reprogramming in the embryo (Ciccarone et al., 
2012).  
This temporal correlation between evidence of activation of components of the DNA 
repair pathway in the paternally-inherited zygotic genome and the onset of a putative 
round of active demethylation may be evidence for role of the DNA repair pathway in 
this process. Yet recent evidence has called into question the level of active 
demethylation that occurs in the zygote. This new work shows that reports of active 
demethylation based on immunolocalisation actual result from a process of progressive 
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antigenic masking during zygotic maturation (Li and O'Neill, 2012). Modification of the 
staining protocols by brief tryptic digestion removed this masking and showed that there 
was no evidence for global active demethylation in the zygote.  
This observation raises the broader question of whether other studies that show marked 
changes in the levels of methylation that have been based upon immunological tools 
might also reflect artefacts of changes in 5meC masking rather than real changes in the 
levels of modification present within cells. Antibody-based methods therefore need to 
be reassessed to address this question.    
1.7. Aims of this thesis 
Covalent modification of cytosine is likely to be an important component of epigenetic 
reprogramming. Much progress has been made in understanding the processes that 
govern methylation, but currently the understanding of the process of demethylation is 
poorly understood. There are questions over whether some evidence for global process 
of demethylation, such as that reported in the male pronucleus of the fertilised embryo, 
occur to the extent that is currently accepted. This thesis will endeavour to identify the 
factors that govern the reliable immunolocalisation of 5meC in a somatic cell type, to 
determine whether changes in chromatin structure and conformation that occur as the 
cells respond to changes in its environment effect the capacity to detect 5meC in the 
nucleus. The outcome of the study should provide robust methods for analysis of the 
global levels and patterns of localisation 5meC in the nucleus. These robust methods of 
global analysis should provide for better tools for investigation of the regulation of these 
epigenetic changes.   
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2. CHAPTER 2: GENERAL MATERIALS AND METHODS 
 
Materials and methods common to a number of chapters are described here. Specific 
materials and methods are given in the relevant chapters.  
2.1. Primary Culture for Mouse Embryonic Fibroblasts (MEFs) 
Embryos (Day 13.5) were removed from pregnant females (C57BL6/JXCBA/He F1) 
after mating with the same hybrid males, and sacrificed by CO2 asphyxiation. Embryos 
were taken by sterile forceps and scissors out of uterus. Heads, limbs and internal 
organs, such as liver, intestines and heart, were removed. Embryo carcasses were 
incubated at 37ºC for 15-20 min in a sterile tube containing trypsin-EDTA (0.25%) 
(Invitrogen Life Technologies, Carlsbad, USA; Cat. No.25200-56), and agitated by 
pipette. The supernatant was transferred into a new sterile tube containing culture 
media. Cells were cultured in complete media containing 90% (v/v) Dulbecco’s 
modified eagle medium (DMEM) with 2mM glutamine and 1mM sodium pyruvate 
(Thermo Fisher Scientific Inc., Utah, USA; Cat. No. SH30243.FS), 10% (v/v) feutal 
bovine serum (FBS) (Invitrogen Cat. No. 10099-141), supplemented with 1% (v/v) 
1xMEM-Non-Essential Amino Acid solution (MEM-NEAA) (Invitrogen, Cat. No. 
11140-050), 50U/ml penicillin (Sigma-Aldrich Co.; St. Louis, MO, USA; Cat. No. 
P3032) and 50µg/ml streptomycin (Sigma, Cat. No. S6501) (DMEM/FBS media). The 
medium was filtered by a syringe driven 0.22µm filter unit (PVDF, Millex-GV; 
Millipore, MA, USA) before use. Cell attachment was complete in 1-3 days. Cell 
culture media was refreshed after 2-3 days. Confluent cells were frozen in the solution 
containing the equal amount (1:1) of freezing solution and complete media. Freezing 
solution contained 20% (v/v) dimethyl sulfoxide (DMSO) (Sigma, Cat. No. D2650), 
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40% (v/v) FBS and 40% (v/v) complete media. Frozen vials were stored in liquid 
nitrogen. No cells from individual embryos were stocked. Embryos from one female 
mouse were mix-cultured and stocked. 
2.2. Cell Culture 
Frozen vials were defrosted at 37-40°C. Cells were suspended in sterile complete media 
and centrifuged for 4 min at 400g. Supernatant was removed. Cells were washed in 
1xPBS, and then incubated in (1:1) trypan blue solution (0.4%) (Sigma, Cat. No. 
T8154) for 10 min at RT. An aliquot of cells excluding (viable cells) or staining (dead 
cells) with trypan blue was counted using haemocytometer (Hirschmann EM Techcolor, 
0.100mm depth) to determine the number of viable cells. Cells were resuspended in 
sterile complete media. Appropriate number of cells was fed either into: (i) dishes with 
sterile cover slips for immunofluorescence or (ii) flasks for flow cytometry. The density 
of cells and the volume of media for each size of dish and flasks used are shown in 
Table 2-1.  
Dish Flask Seeding Density (cell number) Total Media (ml) 
60mm x 16mm T25 200.000-400.000 6-7 
100mm x 17mm T75 500.000-700.000 12-13 
Table 2-1. Cell density and media volume for each flask/dish used in cell culture  
 
For subcultures, cells were washed with 1xDulbecco’s phosphate buffered saline 
(DPBS) (Invitrogen; Cat. No. 14190-144) (Ca 
2+
, Mg 
2+
 free, and pre-warmed to 37°C 
before use) and detached by 0.25% (w/v) trypsin-EDTA (Invitrogen; Cat. No. 25200-56) 
for up to 5 min. Trypsin was inactivated with an equal volume of media (with bovine 
serum) and removed by 4 min centrifugation at 400g. Supernatant was removed. Cells 
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were cultured either in dishes or flasks. Cells used in this thesis were passage 0-10. 
Mouse embryonic fibroblast cells were grown as: (i) during the exponential growth 
phase of sparse culture (proliferative) (1-2 days culture), (ii) as proliferation slowed due 
to approaching confluence of cells (confluent) (3 days culture), and (iii) entry of cells 
into quiescence by serum deprivation for 24h of confluent cells (quiescent) (Figure 
2-1A-C). 
 
Figure 2-1. Typical MEF culture during proliferative, confluent and quiescent states.  
2.3. Cover Slip Preparation 
Cover slips (12mm round) (Livingstone International Pty. Ltd., Cat. No. CS12RD) were 
incubated in 1% HCl (Ajax Finechem Pty Ltd. Cat. No. A256) for 2.5h, and acid was 
removed by the washing in MQW (milli-Q water). Cover slips were incubated in 
ethanol (95% EtOH) (Ajax Chemicals, Cat. No. 5004) overnight at RT, and then 
autoclaved before use.  
2.4. Immunofluorescence for 5-methylcytosine 
After treatment, MEFs were washed with 1xPBS (Sigma, Cat. No. D5773) and fixed 
with 4% (w/v) paraformaldehyde (PFA) (Sigma, Cat. No. P6148) for 30 min at RT. 
Cells were permeabilized with 1xPBS containing 0.75% (v/v) tween-20 (Sigma, Cat. 
No. P7949) and 0.75% (v/v) triton-x (Bio-Rad Laboratories In., CA, USA, Cat. No. 
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161-0407) for 1h at RT. Chromatin was denaturated by HCl (4N) (Ajax Finechem Pty 
Ltd., Cat. No. A256) treatment for 10 min at RT. Acid was removed with extensive 
washing in 1xPBS. Cover slips were drawn using Dako Pen (Dako Pen, Code S2002) to 
remain the solutions applied on cells on cover slips, and then cells were blocked in 30% 
(v/v) sheep serum (Sigma, Cat. No.S3772) in 1xPBT (1xPBS with 0.05% (v/v) tween-
20) at 4°C overnight. Cells were stained using indirect immunofluorescence. The 
primary antibodies (1:60) were monoclonal mouse anti-5-methylcytosine (AbD Serotec 
Ltd., UK; Cat. No. MCA2201), and a non-immune mouse IgG (Sigma-Aldrich Co.; St. 
Louis, MO, USA; Cat. No. M7894) in 2 mg/ml BSA (BSA, bovine serum albumin, 
from Sigma, Cat. No. A1470) in PBT, for 1h at RT. Primary antibody incubation (1:60) 
was followed by a fluorescein-conjugated secondary antibody (FITC-fluorescein 
isothiocyanate) (1:200) (Sigma, Cat No. F6257) in 2 mg/ml BSA in PBT for 1h at RT. 
Cells were washed in 1xPBT, and then mounted in 1xPBS or 1xPBS with 
Hoechst33342 (4µg/ml) (Sigma, Cat. No. B2261). 
2.5. Microscopy and Image analysis 
Cells were analysed by the epifluorescence microscope Eclipse 80i (Nikon Instruments 
Inc., USA). Images were captured using CoolSnap cf camera (Photometrics, AZ., 
USA), and analysed by Image-Pro Plus version 5.0 (Media Cybernetics, Inc., MD., 
USA). Slides were assessed using the same setting of UV power, and images were taken 
using the same exposure time (4 sec) for all treatments of replicates in each experiment. 
Original images without any further adjustments (i.e. contrast) were analysed. Only 
adjustments were applied for preparing representative images. Representative images of 
blue channel (Hoechst) were modified into white/black for the best resolution. Merged 
version of images were in original colours. Objects (nuclei) in images were randomly 
selected using drawing tool and analysed. The total amount of nuclear staining of 
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specific antigens was analysed for at least 80-100 nuclei in each treatment per replicate. 
The total staining (sum value) of specific antigens in each cell (nucleus) was measured, 
and the level of staining is optical density (arbitrary units). The average staining of 
antigen in cells was shown using bar graphs. For the characteristics of focal staining, at 
least 50 foci were analysed in each treatment per replicate. The average number of 
nuclear foci per cell (nucleus) was shown in bar graphs. In some experiments, nuclei 
were subjectively grouped as having a predominant focal or diffuse staining, and the 
number of each group was compared. Undetectable non-immune IgG staining was 
defined as a negative control compared to the specific staining and thus the amount of 
IgG staining (control) could not be measurable. Experiments were performed for at least 
3 independent replicates. 
2.6. Graphs and error bars 
Graphs were made using SPSS or Microsoft Excel. Bar graphs represent optical density 
(arbitrary units) mean +/- s.e.m. (standard error of the mean) of at least 3 independent 
replicates. Bar graphs for the nuclear pattern of staining represent the proportion of 
nuclei (%) with focal or diffuse staining of at least 3 independent replicates for each 
treatment. Bars graphs both for (i) the total proportion of cells (%) assessed viable and 
(ii) the proportion of cells at given stages of the assessed cell-cycle by flow cytometry 
of DNA content represent the average proportion (%) of at least three independent 
replicates. Scatter plots represent the correlation between two parameters along the 
horizontal (X) and the vertical (Y) axes (each axis represents one parameter).  
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2.7. Statistical analyses 
Statistical analyses were performed using SPSS program, version 19. Analyses used 
were: (i) univariate analysis of variance (UNIANOVA) and post-hoc comparisons, (ii) 
binary logistic regression, and (iii) linear regression.  
2.7.1.  Univariate analysis of variance (UNIANOVA) 
Comparisons of the total staining of specific antigens by both immunofluorescence and 
flow cytometry were made using UNIANOVA. The difference in between groups was 
determined by post-hoc test, if p<0.05 obtained in UNIANOVA.  
The proportion of cells at given stages of the assessed cell-cycle by flow cytometry of 
DNA content and the proportion of cells assessed viable by trypan blue were arcsine-
transformed in Microsoft Excel, and compared using UNIANOVA. At least 10.000 total 
events were acquired for cell-cycle analyses, and gated cells were analysed in each 
treatment. Analyses include data from at least 3 independent replicates of each 
treatment per experiment.  
2.7.2. Binary logistic regression analysis 
The nuclear pattern of staining for specific antigens (focal or diffuse) observed by 
immunofluorescence was compared using binary logistic regression analysis. The 
numbers of nuclei either stained or unstained by specific antigens were also compared 
using binary logistic regression.  
2.7.3. Multiple linear regression analysis 
The correlations between two parameters (the staining of two antigens) were analysed 
using multiple linear regression. Correlation coefficients (b) (-1 to 1) between two 
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variables were determined. The correlation is positive, if b ≤ 1. The correlation is 
negative, if b ≥ -1. There is no correlation, if b = 0.  
2.7.4. Statistical significance 
The difference between results was considered by significance levels of p values 
(probability) shown in Table 2-2. 
p value 
 
Symbol  
p<0.05 * 
p<0.01 ** 
p<0.001 *** 
p<0.0001 **** 
Table 2-2. The levels of significance used 
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3. CHAPTER 3: FLOW CYTOMETRIC MEASUREMENT OF DNA 
METHYLATION IN MOUSE EMBRYONIC FIBROBLASTS (MEFs) 
 
3.1. INTRODUCTION 
 
Differential methylation of many CpG sequences within the genome is required for the 
maintenance of genome stability and is involved in establishing epigenetic features such 
as X-chromosome inactivation, heterochromatin formation and parent-of-origin 
dependent mono-allelic gene expression of some loci (imprinted genes) and epigenetic 
reprogramming during embryo development (Hajkova, 2010; Hajkova et al., 2008; 
Momparler R., 2000). Abnormalities in these normal patterns of 5meC programming 
are associated with a range of developmental abnormalities i.e. Rett syndrome (Goffin 
et al., 2012), loss of genomic imprinting (Kisseljova and Kisseljov, 2005; Li et al., 
1993) and some forms of oncogenesis (Chen et al., 2009; Chim et al., 2007; Hernandez-
Blazquez et al., 2000; Lund and Lohuizen, 2004; Simpkins et al., 1999; Soares et al., 
1999; Wlazlinski et al., 2007; Wu et al., 2009).  
Analysis of 5meC is an increasingly important tool for epigenetic research. Because of 
its implication in the regulation of gene function much attention, and many of the 
available tools for analysis, have focussed on base-level analysis within regulatory 
regions of expressed genes, yet most of the 5meC within the genome occurs outside of 
the expressed regions (Jeltsch, 2002). Furthermore, many genes do not contain 
identifiable CpG-enriched regions that are methylated within their regulatory regions 
(Bird, 2002). Biochemical analysis of 5meC has been further complicated by the recent 
observations that ‘gold-standard’ approaches, such as bisulfite conversion (Bar-Nur et 
al., 2011; Bocker et al., 2011; Herman et al., 1996; Karouzakis et al., 2009; Walker et 
al., 2011) and HpaII/MspI digestion (Nestor et al., 2010) do not distinguish between 
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5meC and its important metabolites such as 5hmC. Methods that rapidly and selectively 
analyse changes in the global levels in each of these covalent modifications are, 
therefore, important tools for epigenetic research. Stable analytical platform 
technologies will facilitate the screening of regulatory pathways and development of 
therapeutic approaches. 
Antibody-based analytical tools have been widely used for 5meC analyses and 
antibodies that distinguish between the known cytosine modifications are widely 
available. Immuno-microscopy can potentially provide information on changes in the 
level and pattern of localisation of methylation within individual cells but is time-
consuming and subject to some subjectivity of analysis. Flow cytometry has been used 
for analysis of global CpG methylation (Habib et al., 1999; Karouzakis et al., 2009; 
Schneider and Fagagna, 2012) and has the advantage of allowing rapid quantitative 
analysis of large numbers of cells (Veal et al., 2000). Reliable use of antibody-based 
methods, however, rely upon the epitope (5meC) being fully solvent exposed and thus 
readily capable of equilibrium binding with the labelling antibody.  
Recently, it was shown that a good amount of the reported 5meC remodelling occurring 
within the early embryo could be accounted for by changes in the level of epitope 
masking by chromatin-associated proteins rather than actual changes in 5meC levels (Li 
and O'Neill, 2012). Tryptic digestion of cellular proteins unmasked the 5meC antigen 
and revealed a different and much more stable pattern of nuclear 5meC during embryo 
development (Li and O'Neill, 2012).  
In this chapter, the pattern of methylation of mouse embryonic fibroblasts was 
examined to develop and validate methods for the analysis of changes in global 5meC 
levels by flow cytometry and epifluorescence microscopy.  
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3.2. MATERIALS AND METHODS 
3.2.1. Cell Culture 
Confluent mouse embryonic fibroblast (MEF) cells were cultured in Dulbecco’s 
modified eagle medium (DMEM) either with phenol red (Thermo Fisher, Cat. 
No.SH30243.FS) or without phenol red (Thermo Fisher, Cat No. SH30284.01). Media 
were supplemented with 10% (v/v) fetal bovine serum (FBS) (Invitrogen), 1% (v/v) 
1xMEM-Non-Essential Amino Acids solution (Invitrogen), 50U/ml penicillin (Sigma) 
and 50µg/ml streptomycin (Sigma)  at 37°C with 5% CO2 in air. All cells used in the 
study were passage 0-9 after collection. In some experiments methylation of cells 
during their replication was blocked by treatment with 5-Aza-2'-deoxycytidine (5-AZA) 
(Sigma, Cat No. A3656) at concentrations of 0, 2.5, 5 and 10µM in culture media for 
24h. 
 
3.2.2. Immunofluorescence for 5-methylcytosine 
 
After treatment, MEFs were washed with 1xPBS and fixed with 4% (w/v) PFA for 30 
min at RT. Cells were permeabilized with 1xPBS containing 0.75% (v/v) tween-20 and 
0.75% (v/v) triton-x for 1h at RT. Chromatin was denaturated by HCl (4N) (Ajax 
Finechem Pty Ltd, Cat. No. A256) treatment for 10 min at RT. Acid was removed with 
extensive washing in 1xPBS and in some experiments cells were treated with trypsin 
(for 1 min) after acid. Following antigenic retrieval, cells were blocked in 30% (v/v) 
sheep serum (Sigma, Cat. No. S3772) in 1xPBT (1xPBS with 0.05% (v/v) tween-20) at 
4°C overnight. Cells were incubated in primary antibodies (1:60): mouse monoclonal 
anti-5-methylcytosine (5meC) (AbD Serotec Ltd., UK; Cat. No. MCA2201), or a non-
immune mouse IgG (Sigma; Cat. No. M7894) in 2 mg/ml BSA (Sigma, Cat. No. 
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A1470) in PBS with 0.05% triton-x (w/v), for 1h at RT. Cells were washed in 1xPBS 
for 30 min, and then were incubated with a fluorescein-conjugated secondary antibody 
(FITC) (1:200) (Sigma, Cat No.F6257) in 2 mg/ml BSA in PBS with 0.05% triton-x 
(w/v) for 1h at RT in the dark. Cells were washed in 1xPBS with 0.05% (v/v) tween-20 
and then mounted with 1xPBS.  
3.2.3. Microscopy  
Cells were analysed by the epifluorescence microscopy, Eclipse 80i (Nikon Instruments 
Inc., USA). Images were captured by camera, CoolSnap cf (Photometrics, AZ., USA), 
and analysed by Image-Pro Plus version 5.0 (Media Cybernetics, Inc., MD., USA). 
Images were taken using the same illumination and microscope settings for all images. 
In some experiments, single nuclei stained with 5meC were selected to analyse. The 
mean intensity of nuclear staining was assessed using the area of interest tool. 
Experiments were performed as at least 3 independent replicates.  
3.2.4. Flow cytometric measurement for cellular 5meC staining 
After treatment, cells were washed with 1xPBS and detached by 0.25% trypsin- EDTA 
for up to 5 min. Trypsin was inactivated with an equal volume of DMEM/FBS 
(complete) media and removed by 4 min centrifugation at 400g. Cells were washed with 
1xPBS (w/v) and fixed with 4% (w/v) PFA for 30 min. Fixed cells were permeabilized 
by 1xPBT (1xPBS including 0.75% (v/v) tween-20 and 0.75% (v/v) triton-X) for 1h. 
Chromatin was denaturated by treatment with 4N HCl, for 10 min. Cells were washed 
with 1xPBS for 30 min to remove acid and in some experiments cells were treated with 
trypsin (for 1 min) after acid. Following antigenic retrieval, cells were blocked in 30% 
(v/v) sheep serum (Sigma, Cat. No. S3772) in 1xPBT overnight. Cells were stained in 
primary antibodies (1:60) mouse monoclonal anti-5-methylcytosine (AbD Serotec Ltd, 
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UK; Cat. No 5MCA2201) or a non-immune mouse IgG (Sigma; Cat. No. M7894) in 2 
mg/ml BSA in 1xPBT for 1h, and then washed with 1xPBS for 30min. Cells then were 
incubated with a fluorescein-conjugated secondary antibody (FITC) (1:200) (Sigma, 
Cat. No. F6257) (in 2 mg/ml BSA in 1xPBT) for 1h in the dark. Cells were washed in 
1xPBS 3 times by centrifugation at 900g for 5 min. In some experiments (using FL1-H), 
2.5 µl 7-Aminoactinomycin-D (7-AAD) (Sigma, Cat. No. A9400) (100µg/ml) per assay 
was added to the cell preparation as a final step to stain nuclei. Equilibrium staining 
with 7-AAD was reached after approximately 4 min incubation. All steps, excluding 
blocking at 4ºC, were performed at room temperature. Stained cells were analysed by 
flow cytometry. At least 10,000 total events were acquired for each treatment per 
replicate. Total 5meC methylation was gathered either at fluorescence channel-1 (FL1-
H) (excitation at 488nm, emission at 519nm) for FITC label or at fluorescence channel-
3 (FL3-H) for PerCP label (excitation at 488nm, emission at 678nm). Flow cytometry 
instrument (BD FACSCalibr, BDIS San Jose Ca. USA) was set for maximum 
fluorochrome sensitivity using Calibrate
TM
 standardisation microspheres. 
3.2.5. Antibodies  
Primary antibodies tested were: (i) mouse monoclonal anti-5-methylcytidine (AbD 
Serotec, MCA2201, Clone 33D3): (ii) rabbit polyclonal anti-histone 3(acetyl K9) 
(Abcam, MA, UK, ab4441): (iii) rabbit monoclonal anti-phospho-Akt(Ser473)(193H12) 
(Cell Signalling Technology Inc. MA, 4058): and (iv) rabbit monoclonal anti-β-actin 
(13E5) (Cell Signalling Technology, 4970). Non-immune control antibodies were 
mouse IgG (Sigma, M7894) and rabbit IgG (Sigma, I5006). Primary antibody binding 
was detected with secondary antibodies coupled with fluorescein isothiocyanate (FITC) 
(Sigma, F6257).  
50 
 
3.2.6. Cell-cycle analyses 
After 5-AZA treatment, cells were washed with 1xDulbecco’s phosphate buffered saline 
(DPBS) (Invitrogen; Cat. No. 14190-144) (Ca 
2+
, Mg 
2+
 free, and pre-warmed to 37°C 
before use) and detached by 0.25% trypsin-EDTA (Invitrogen; Cat. No. 25200-56) for 
up to 5 min. Trypsin was inactivated with an equal volume of complete media and 
removed by 4 min centrifugation at 400g. Cells were washed in 1xPBS, and then 
incubated in the dark with Propidium iodide (PI) (Sigma; Cat. No. P4170) in 2% triton-
x/PBS (v/v) (final concentration 50mM) for 30 min at RT. DNA mass in G1, S and G2 
phases of the cell-cycle was analysed by fluorescence channel-2 (FL2-A) of flow 
cytometry instrument (BD FACSCalibr, BDIS San Jose Ca. USA). The analysis of 
DNA mass over the cycle is based on DNA content in the cells. Cell populations were 
analysed using BD CellQuest
TM 
Pro software (BD FACSCalibr, BDIS San Jose Ca. 
USA). Dot plots and histograms were made using BD CellQuest
TM  
Pro software.  
3.2.7. Statistics 
Statistical analyses were performed by SPSS program, version 19. Graphs were made 
using SPSS or Microsoft Excel. The level of 5meC staining was analysed using 
univariate analyses of variance (UNIANOVA).  
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3.3. RESULTS  
 
3.3.1. Measurement of cytosine methylation (5meC) by flow cytometry 
 
The protocol for flow cytometric measurement of 5meC staining was based on the 
immunofluorescence method for 5meC staining in embryos which was previously 
optimised in our laboratory (Section 3.2.2). The further modification of this 
methodology to make it suitable for use with MEFs was performed. Confluent MEFs 
were detached by trypsin and fixed with 4% PFA for 30 min. Cells were permeabilized 
and stained as detailed in the protocol.  
Fluorescence microscopy showed clear nuclear staining of 5meC and little staining was 
detected in IgG control treated cells after acidic treatment for chromatin denaturation 
(Figure 3-1A). No staining was detected when cells were not denatured by acid 
(untreated) (Figure 3-1A). Flow cytometric measurement of cells (gated using SSC/7-
AAD dot plot) (Figure 3-1B) showed that the FL1-H channel consistently displayed a 
signal in the non-immune IgG staining which was not different from the anti-5meC 
stained cells (Figure 3-1C). To determine whether this was caused by the nature of 
primary antibody interactions several other antibodies were assessed: anti-beta-Actin, 
anti-phospho-Akt (Ser473) and anti-histone 3 acetyl K9 (H3K9). Cells stained with 
these primary antibodies also showed high levels of background staining which 
prevented detection of a defined signal (Figure 3-1D-F). The signal to noise ratio (S/N) 
is given for each antibody in Figure 3-1C-F. The typical background staining of live 
MEFs with FL1-H detector is shown in Figure 3-1G and it shows that high background 
(autofluorescence) staining was caused by autofluorescence of in cells irrespective of 
the fixation method or staining antibody used. 
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Figure 3-1. Analysis of 5meC, beta-actin, phospho-Akt (ser473) and histone 3 acetyl 
lysine 9 staining with FITC labelled secondary antibodies.  
Confluent MEFs were stained with non-immune IgG control or primary antibodies. (A) 
Representative images of immunofluorescence microscopy of cells are shown for 5meC 
after acidic treatment (HCl) or without acidic denaturation (Untreated). Negative 
staining with non-immune IgG in both treatment. Bar is 10 µm. (B) Cells were gated 
using a side scatter/7AAD dot plot (G1, Gate 1) and analysed with FL1-H detector. (C) 
Fluorescence of anti-5meC primary antibody (Signal) and non-immune IgG (Control) 
are shown. The same methodology was used with other well-validated antibodies (D) 
anti-beta-actin, (E) anti-phospho-Akt (ser473), and (F) anti-histone 3 acetyl lysine 9 
(H3K9), and a further control (G) was analysis of live cells with FL1-H detector 
(Autofluorescence). MFI: Mean fluorescence intensity, S/N - Signal/Noise ratio from 
one replicate. 
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3.3.2. Sources of autofluorescence 
The presence of phenol red indicator in culture media is known to cause fluorescence in 
some settings (Benson et al., 1979; Fiorelli et al., 1995; Kim et al., 2007) so that cells 
were cultured either in the presence or absence of phenol red for several passages. The 
extent of autofluorescence reduced with passage number and the level was lower overall 
in the absence of phenol red (Figure 3-2A and B) compared with cells cultured in media 
containing phenol red (Figure 3-2C). Yet, even in the absence of phenol red 
autofluorescence still persisted at an unacceptable level, preventing detection of 5meC 
(Figure 3-2D-F). Trypan blue can quench some sources of autofluorescence (Loike and 
Silverstein, 1983; Mosiman et al., 1997), yet various concentrations (1, 2, 4, 8 µg/ml) 
were examined and trypan blue was found to have little effect on autofluorescence in 
live MEFs and had only a small effect in fixed cells compared to their dye-free 
counterparts (Figure 3-3A-C).  
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Figure 3-2. Effect of phenol red in culture media and the number of culture passages 
on autofluorescence.  
(A) MEFs were analysed after increasing number of passages (0, 5-9) in media with 
(+PR) or without phenol red (-PR). Confluent cells were assessed for autofluorescence 
or stained with anti-5meC or non-immune IgG. Autofluorescence of cells for each 
passage (A) without or (B) with phenol red. (C) The relative changes in the mean 
fluorescence intensity of autofluorescence of cell culture in the presence or absence of 
phenol red are shown (PR+/- ratio). (D) The cells were gated using SSC (side scatter)-
FSC (forward scatter) dot plot, and then examined for anti-5meC or non-immune IgG 
for cells cultured in the (E) absence or (F) presence of phenol red. S/N - Signal/Noise 
ratio from one replicate. 
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Figure 3-3. Effect of trypan blue (TB) use on autofluorescence in MEFs.  
(A) The mean fluorescence intensity (MFI) of autofluorescence of confluent live and 
fixed MEFs after trypan blue treatment is shown. (B-C) Confluent cells were stained 
with anti-5meC or non-immune IgG and FITC-labelled secondary antibody. Stained 
cells were treated with trypan blue (2µg/ml) for 10 min, then analysed with FL1-H. 
Staining distribution of anti-5meC and non-immune IgG staining (B) without trypan 
blue (-TB) or (C) with trypan blue (+TB) is shown. S/N - Signal/Noise ratio and MFIs 
from one replicate. 
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3.3.3. Autofluorescence pattern of MEFs  
 
High levels of autofluorescence were detected in independent samples by the FL1-H 
(Figure 3-4A-i), FL2-H (A-ii) and FL4-H (A-iv) detectors when FITC was used as the 
fluorescence secondary antibody. By contrast, a low level of autofluorescence was 
detected in the FL3-H channel for all samples (Figure 3-4A-iii). PerCP-conjugated 
secondary antibody which emits at 690 nm (detected by FL3-H) was therefore chosen 
for use. It was not possible to use a DNA dye (7-AAD) due to its spectral overlap. The 
FL3-H channel was gated using a SSC-FSC dot plot (Figure 3-4B-i) and the PerCP 
signal and autofluorescence were acceptably low in the FL3-H channel (Figure 3-4Bii-
iii). Strong discrimination between non-immune control and anti-5meC staining was 
observed using this secondary antibody (S/N: 18.3) (Figure 3-4B-iv).  
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Figure 3-4. Spectral properties of autofluorescence of MEFs and the effect of 
analysis with an alternative fluorophore. 
(A) Autofluorescence of independent samples from confluent live MEFs was assessed 
with channels (i) FL1-H, (ii) FL2-H, (iii) FL3-H, and (iv) FL4H. Principally the 
emission spectra of green, yellow, orange, red fluorochromes are detected by FL1-H, 
FL2-H, FL3-H and FL4-H, respectively. (B) Since autofluorescence was consistently 
low in (iii) FL3-H a fluorophore favoured for detection by this channel – PerCP was 
tested. Staining of MEFs for anti-5meC or non-immune IgG with a PerCP-labelled 
secondary antibody was analysed. (i) cell gated for analysis (G) and cell population 
analysed. (ii) staining with secondary antibody alone, (iii) autofluorescence in live 
cells, and (iv) detection of ant-5meC and non-immune IgG with PerCP-labelled 
secondary antibody are shown. The results are representative of at least three 
independent replicates. (MFI: mean fluorescence intensity, S/N: signal to noise from 
one replicate)  
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To determine the highest signal for 5meC staining, a range of primary antibody dilution 
(1:60, 1:120, 1:180, 1:240) was examined. PerCP was used at the dilution (1:21) 
recommended by the manufacturer. Cells were gated using a SSC-FSC dot plot (Figure 
3-5A). Autofluorescence (Figure 3-5B) and PerCP signal alone (Figure 3-5C) showed 
acceptably low staining at FL3-H. The highest 5meC signal strength was found at 1:60 
(p<0.0001), compared to other concentrations (Figure 3-5D). Non-immune IgG control 
at all concentrations gave a similar low level of background staining (Figure 3-5E).  
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Figure 3-5. Optimisation of 5meC staining labelled by peridinin-chlorophyll-protein-
complex (PerCP) at FL3-H by flow cytometry in MEFs.  
Confluent cells were fixed, permeabilized and treated acid followed by blocking. Cells 
were incubated with primary antibodies and tagged with PerCP (1:21). (A) Cells were 
gated (G1) using a SSC- FSC dot plot. MFI for (B) Autofluorescence and (C) PerCP 
alone are shown. (D) Overlays of 5meC antibody dilutions, 1:60, 120, 180 and 240 at 
FL3-H is shown. (E) Overlays of non-immune IgG control antibody dilutions: 1:60, 
120, 180 and 240 at FL3-H are shown. The signal strength for 5meC at 1:60 was 
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significantly different from other concentrations, but IgG control was not different at 
any concentration and acceptably low in any compared to 5meC. Experiment was 
performed at least five independent replicates. At least 10.000 total events were 
acquired for each treatment per replicate. **** p<0.0001  
 
The effect of further antigen retrieval by trypsin treatment on the 5meC detection was 
next analysed. Immunolocalisation showed that in confluent MEFs brief exposure of 
fixed cells to 0.25% trypsin for 1 min after acid treatment caused an increase in the 
intensity of the 5meC signal detected by epifluorescence microscopy (Figure 3-6A). 
Flow cytometry of cells treated in this way also showed that tryptic digestion caused a 
significant (p<0.05) increase in the average level of 5meC staining detected by flow 
cytometric analysis compared to those treated with acid alone (Figure 3-6B-C).  
To further assess the ability of flow cytometry and microscopy to detect global changes 
in the level of cellular 5meC, proliferating cells were treated with a range of 
concentrations of the DNA methyltransferase inhibitor 5-Aza-2'-deoxycytidine. This 
treatment blocks maintenance methylation of the hemi-methylated cytosine generated 
during DNA replication. Proliferative MEFs were incubated in this inhibitor for 24h to 
ensure that at least one round of DNA replication was affected. Cell-cycle analyses 
showed that treatment at 2.5 and 5 µM had no effect on cell-cycle dynamics, but at 10 
µM there was a redistribution towards a higher proportion of cells in S-G2/M transition 
(p<0.05) (Figure 3-7A). This analysis showed that global level of cellular methylation 
was lower for each concentration of 5-Aza-2'-deoxycytidine compared to untreated cells 
(p<0.05) (Figure 3-7B). Immunofluorescence microscopy showed a good agreement 
with the decrease in the level of 5meC after the inhibitor (p<0.05) (Figure 3-7C). This 
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shows that both microscopy and flow cytometry were capable of detecting the reduction 
in global methylation levels caused by inhibition of DNMT. 
 
Figure 3-6. The effect of tryptic-digestion on the retrieval of 5meC antigen in MEFs.  
Confluent MEFs fixed and permeabilized. They were then either untreated or acid-
treated (HCl) or treated with trypsin (0.25%) for 1 min after acid (HCl + trypsin) and 
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stained with anti-5meC. (A) Immunofluorescence microscopy showed that trypsin 
treatment increased staining of 5meC (FITC-labelled) compared to acidic treatment 
alone. Scale bar 10 micron. (B) Flow cytometric detection of (i) anti-5meC or (ii) non-
immune IgG with PerCP-labelled secondary antibody is shown for staining followed no 
treatment (green line), acid-only treatment (red line) and acid + trypsin pre-treatment 
(black line). (C) The mean fluorescence intensity (+/-s.e.m.) after the three antigen 
preparation methods is shown for (i) staining for anti-5meC, and (ii) non-immune IgG. 
* p<0.05, ** p<0.01. Results are the outcomes of three independent replicates.  
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Figure 3-7. The effect of the inhibition of DNA methyltransferase on the detection of 
cellular levels of 5meC.  
Proliferative MEFs were incubated with a DNA methyltransferase inhibitor 5-Aza-2'-
deoxycytidine at concentration of 0, 2.5, 5 or 10µM for 24h. (A) Cell-cycle analysis was 
performed on Propidium iodide (PI) stained MEFs after treatment with inhibitor. (B) 
Distribution of anti-5meC staining after acid and trypsin treatment for antigen retrieval 
for cells after inhibitor treatment are shown. (C) Immunofluorescence microscopic 
images of representative cells and the level of 5meC of cells after inhibitor treatment 
are shown. Bar is 10 µm, * p < 0.05, **** p<0.0001. Results are from two independent 
replicates.      
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3.4. DISCUSSION 
This chapter shows that the 5meC antigen can be detected in MEFs by both 
epifluorescence microscopy and flow cytometry. Acid-induced denaturation of 
chromatin was required for detection of antigen, yet the level of detection was increased 
by further brief tryptic digestion. The observation that the level of the 5meC antigen 
detected by both methods decreased after inhibition of DNMT is indicative that both 
these methodologies are capable of detecting meaningful changes in global levels of 
5meC in the nucleus of MEFs.  
Most reported antibody-based analyses of cellular mCpG have used brief exposure of 
fixed cells to acid (typically 2-4 M HCl) (Ciccarone et al., 2012; Salvaing et al., 2012) 
with the expectation that this treatment denatures chromatin and thus expose the antigen. 
This is supported by the failure to detect 5meC in fixed cells without HCl treatment but 
its observation after treatment. Recent analysis in the early embryo, however, has 
revealed that a proportion of 5meC remains masked after acid-treatment but is detected 
after further brief tryptic digestion (Li and O'Neill, 2012). This chapter shows that partial 
antigenic masking of 5meC also occurs in MEFs, indicating there is a proportion of the 
methylated genome that is not solvent exposed following acid-induced denaturation 
of chromatin, but remains masked by the protein-dependent conformation of the 
genome. An important observation made by epifluorescence microscopy was that much 
of the methylation occurred as numerous distinct staining-intense foci scattered 
throughout the nuclei. While some of these foci whether present after acid-treatment 
alone, their size and number appeared to increase after trypsin treatment. The increase 
accounted for much of the increased 5meC detected after tryptic-digestion. The 
extensive heterogeneity in this pattern of staining was not readily assessed using the 
flow cytometry methods used in this study. 
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The study found an unexpected high level of non-specific autofluorescence using some 
detection channels within flow cytometry. Autofluorescence can derive from a range of 
different sources in the cell, such as riboflavins, cytochromes, NADH, elastin, collagen 
and lipofuscins, and the levels and source of these is likely to vary considerably between 
cell sources (Billinton and Knight, 2001). The sources of this autofluorescence were not 
defined but found to be overcome by use of the FL3-H detection channel. The result 
shows that careful analysis of the levels of autofluorescence will be required for each 
cell type and model used.   
It is now recognised that the gold-standard methods of cellular analysis of cytosine 
methylation most widely used to date do not discriminate between methylated cytosine 
and its various metabolites without special adaption (Huang et al., 2010; Jin et al., 2010; 
Nestor et al., 2010). This may not change the interpretation of methylomes if each of the 
modifications has functional equivalence, yet a body of evidence is building 
suggesting this may not be the case (Yu et al., 2012b). Thus, convenient 
assays that discriminate between these range of covalent modifications of cytosine are 
essential for developing a detailed understanding of the various roles of these 
modifications to genomic structure and function.  
This analysis shows that both epifluorescence microscopy and flow cytometry provide 
convenient methods for the analysis of global patterns of nuclear methylation. It shows 
that acid denaturation and tryptic digestion revealed pools of 5meC with different 
requirements for solvent exposure. The results show that both acid and trypsin 
treatment epitope retrieval resulted better retrieval of the antigen, and are thus required 
for a detailed analysis of global 5meC in MEFs. Flow cytometry has the advantage of 
allowing convenient analysis of large numbers of cells, while epifluorescence 
microscopy allows analysis of the extensive heterogeneity of staining that was 
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observed within nuclei. Since much of the trypsin-sensitive pool of 5meC was found 
within staining-intense foci scattered through the nuclei, the use of immuno-
localisation microscopy is best suited to examining changes in this pool of 5meC . This 
form of analysis will be the primary technique for the remaining studies of this thesis.  
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4. CHAPTER 4: FURTHER ANALYSIS OF THE REQUIREMENTS FOR 
ANTIGENIC UNMASKING OF DNA METHYLATION IN MEFs 
4.1. INTRODUCTION 
 
Methylation may have important roles in the maintenance of genome stability as well as 
influencing patterns of gene expression. Patterns of methylation can also influence 
chromatin structure within the nucleus. For example, DNA in heterochromatic regions 
is commonly hypermethylated (Hajkova et al., 2008).  
The use of immunolocalisation with specific antibodies potentially allows the 
assessment of changes in methylation and has the added advantage of allowing the 
detection of changes in the localisation of methylation within the architecture of the 
nucleus (Brown et al., 2008; Miller et al., 1974). It has the further very important 
advantage of being able to distinguish between the known range of modifications to 
cytosine (5meC, 5hmC, 5caC and 5fC). Conventional methods of chemical analyses, 
such as bisulfite or Hpa1/Msp1 restriction analyses do not routinely achieve this 
discrimination (Huang et al., 2010; Nestor et al., 2010). These advantages of 
immunolocalisation of 5meC mean it is a potentially important tool for epigenetic 
research, but its meaningful use requires that the conditions required for valid detection 
of 5meC in situ are understood and defined. The previous chapter showed that 
immunostaining detected global changes in nuclear methylation but that this required 
denaturation of chromatin by acid and further epitope retrieval by trypsin treatment. The 
results also revealed that methylation was heterogeneously distributed throughout the 
nucleoplasm of MEFs.  
Chromatin conformation and structure in cells varies greatly during ontogeny and 
throughout the cell-cycle (Terzoudi et al., 2011; Woodcock and Ghosh, 2010). Major 
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changes are in chromatin studies associated with the epigenetic reprogramming that 
occurs in the early embryo (Hajkova et al., 2008) and in oncogenesis (Jiang et al., 2012; 
Kamiyama et al., 2012). In the early embryo the loss of 5meC staining was caused by 
conformational changes to chromatin. This meant that acid denaturation was not 
sufficient to faithfully retrieve the 5meC antigen (Li and O'Neill, 2012) and further 
treatment by tryptic digestion was required for faithful retrieval of the 5meC antigen.  
While profound changes in immune-detectable 5meC have been observed in cells 
undergoing epigenetic transitions using conventional methodology, it is also common to 
see marked heterogeneity in the levels of 5meC staining between cells of the same 
lineage (Schneider et al., 2010; Xie et al., 2011). Currently, methods of chemical 
analysis do not have sufficient levels of accuracy and sensitivity to allow reliable 
measurements of global level of 5meC in individual cells. Consequently, it is not 
possible to assess at this time whether this heterogeneity reflects true changes in 
epigenetic information between cells or whether it reflects heterogeneity in staining 
outcomes.  
Changes in the levels of 5meC antigen detected in the early embryo are accompanied by 
dynamic changes in chromatin structure including the accumulation of extensive 
heterochromatic regions (Hajkova et al., 2008; Wongtawan et al., 2011), and dynamic 
changes in histone post-translational modifications (Hajkova et al., 2008; Santos et al., 
2005). Changes in the proliferative status of cells are also known to be associated with 
extensive changes in the structure of chromatin (Grigoryev et al., 2004; Kreiling et al., 
2011; Weisman-Shomer et al., 1979; Zwelling et al., 1987), and are therefore of interest 
to determine whether changes chromatin conformation with a cell’s proliferative status 
cause marked changes in the levels and patterns of immune-detectable 5meC.  
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In this chapter, the conditions for antigenic retrieval of 5meC in MEFs are 
systematically investigated and the effects of the cell’s proliferative state on the solvent 
exposure of 5meC assessed. The nature of the focal pattern of antigen distribution in 
MEFs is investigated. The study compares 5meC staining with staining of MBD1 (a 
proxy marker for 5meC) and the requirements for retrieval of the MBD1 epitope 
assessed, and MBD1 was investigated using fluorescence microscopy to detect the level 
of trypsin-sensitive masking of the 5meC and MBD1 antigens in mouse embryonic 
fibroblasts and the nature of DNA methylation within the chromatin. This chapter also 
aimed to define the conditions required for the reliable analysis of epigenetic structural 
features within the nucleus.   
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4.2. MATERIALS AND METHODS 
 
4.2.1. Cell Culture 
MEFs were in one of three different growth states: proliferative, confluent, or quiescent 
culture. Cells were cultured in media including fetal bovine serum (FBS) (10% v/v). To 
achieve quiescence confluent cells were cultured in media where FBS was replaced by 
bovine serum albumin (BSA) (3mg/ml) for 24h (quiescent cells).  
4.2.2. Antigenic retrieval  
For 5meC staining, confluent MEFs were treated with trypsin (0.25%) either for 0, 1 or 
2 min after HCl either for 10 or 20 min. For MBD1 staining, confluent MEFs were 
treated with trypsin (0.25% w/v) either for 0, 1, 1.5, 2 or 2.5 min after HCl for 10 min.  
4.2.3. Immunofluorescence for 5-methylcytosine (5meC)  
After treatment, MEFs were washed with 1xPBS and fixed with 4% (w/v) PFA for 30 
min at RT. Cells were permeabilized with 1xPBS containing 0.75% (v/v) tween-20 and 
0.75% (v/v) triton-x for 1h at RT. Chromatin was denaturated by HCl (4N) treatment 
for 10 min at RT. Cells were washed with 1xPBT for 30 min. Cells were then treated 
either with trypsin (0.25%) or not (detailed in section 4.2.2). Trypsin was inactivated by 
addition of equal volume of pre-warmed media including 90% (v/v) DMEM, 3 mg/ml 
BSA and 10% (v/v) sheep serum for 1 min at 37°C. Cells were incubated with 
deactivation media for 2 min at 37°C. Cells were washed with 1xPBT after acid or/and 
trypsin. Cells then were blocked in 30% (v/v) sheep serum in 1xPBT at 4°C overnight. 
Cells were incubated in primary antibodies (1:60): mouse monoclonal anti-5meC (AbD 
Serotec Ltd., UK; Cat. No. MCA2201), or a non-immune mouse IgG (Sigma; Cat. No. 
M7894), for 1h at RT. Cells were then incubated with a fluorescein-conjugated antibody 
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(FITC) (1:200) (Sigma, Cat No.F6257) for 1h at RT in the dark. Cells were washed in 
1xPBT and then mounted either with 1xPBS or 4µg/ml (v/v) Hoechst 33342 (Sigma, 
Cat. No. B2261) in 1xPBS.  
4.2.4. Immunofluorescence for methyl-binding domain-1 (MBD1) protein 
 
After treatment, MEFs were washed with 1xPBS and fixed with 4% (w/v) PFA for 30 
min at RT. Cells were washed with 1xPBT for 30 min. Cells were permeabilized with 
1xPBS containing 0.5% (v/v) tween-20 and 0.5% (v/v) triton-x for 40 min at RT. 
Chromatin was denaturated by HCl (4N) (containing 0.1% (v/v) triton-x) treatment for 
10 min at RT. Cells were washed with 1xPBT for 30 min. Cells were treated either with 
trypsin or not (detailed in section 4.2.2). Trypsin was inactivated an equal volume of 
pre-warmed media including 90% (v/v) DMEM, 3 mg/ml BSA and 10% (v/v) sheep 
serum, for 1 min at 37°C. Cells were incubated with deactivation media once more for 2 
min at 37°C. Cells were washed with 1xPBT after acid or/and trypsin. Cells then were 
blocked in 30% (v/v) goat serum (Sigma, Cat. No. G9023) in 1xPBT at 4°C overnight. 
Cells were incubated in primary antibodies (1:50): rabbit polyclonal antibody against 
MBD1 (Abcam, Cat. No. ab3753), or a non-immune rabbit IgG (Sigma, Cat. No. I5006) 
in 2 mg/ml BSA in 1xPBT at 4°C overnight. Cells were washed with 1xPBT for 10 min. 
Cells were then incubated with a fluorescein-conjugated antibody (Goat anti-rabbit IgG-
FITC, Sigma, Cat. No. F1262) for 1h at RT in the dark. Cells were washed in 1xPBT 
and then mounted either with 1xPBS or 4µg/ml (v/v) Hoechst 33342 in 1xPBS.  
4.2.5. Immunofluorescence for double staining of 5meC and MBD1  
After treatment, MEFs were washed with 1xPBS (w/v) and fixed with 4 % (v/w) PFA 
for 30 min at RT. Cells were washed with 1xPBT (w/v) for 30 min. Cells were 
permeabilized with 1xPBS including 0.5% (v/v) triton-x and 0.5% (v/v) tween-20 for 40 
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min at RT. Cells were treated with 4N HCl containing 0.1% (v/v) triton-x for 10 min at 
RT. Acid was removed by extensive washing with 1xPBT. Cells were treated with 
trypsin (0.25%) either for 0 or 1 min at 37°C. Trypsin was inactivated with the equal 
volume of pre-warmed media including 90% (v/v) DMEM, 3 mg/ml BSA and 10% 
(v/v) sheep serum, for 1min at 37°C. Cells were incubated with deactivation media for 2 
min at 37°C. Cells were washed with 1xPBT (w/v) followed by blocking in serum mix 
containing 10% (v/v) goat and 30% (v/v) sheep serum in 1xPBT at 4°C overnight. Cells 
were incubated in primary antibodies: rabbit anti-MBD1 (1:50) or non-immune rabbit 
IgG (1:50) in 2 mg/ml BSA in 1xPBT overnight at 4°C. Cells were washed with 1xPBT 
for 10 min at RT followed by incubation with primary antibodies: mouse anti-5meC 
(1:60) or non-immune mouse IgG (1:60) in 2 mg/ml BSA in 1xPBT for 1h at RT. Cells 
were washed with 1xPBT (w/v) for 30 min. Cells then were incubated with secondary 
antibody mix including anti rabbit-Texas Red (1:200) and anti mouse-FITC (1:200) in 2 
mg/ml BSA in 1xPBT (w/v) for 1h in the dark at RT. Cells were washed with 1xPBT 
(w/v) for 30 min at RT. Cells were mounted with 1xPBS including Hoechst (4µg/ml).  
4.2.6. Immunofluorescence for HP1-β protein  
Confluent MEFs were washed with 1xPBS (w/v) and fixed with 4 % (v/w) PFA for 30 
min at RT. Cells were washed with 1xPBS (w/v), and then permeabilized with 1xPBS 
including 0.25% (v/v) triton-X for 1h at RT. Cells were treated with 4N HCl for 10 min 
at RT. Cells were washed with 1xPBT (w/v) (1xPBS including 0.05% (v/v) tween-20) 
for 30 min at RT. Cells were then blocked in 30% (v/v) sheep serum in 1xPBT for 2h at 
RT. Cells were incubated in primary antibody mouse anti-HP1-β (1:200) (Abcam, Cat. 
No. ab101425), or mouse IgG (1:200) (Sigma; Cat. No. M7894) in 2 mg/ml BSA in 
1xPBT (w/v) at 4°C overnight. Cells were washed with 1xPBT (w/v) for 30 min at RT. 
Cells then were incubated with secondary antibody anti-mouse FITC (1:200) (Sigma, 
73 
 
Cat. No. 6257) in 2 mg/ml BSA in 1xPBT (w/v) for 1h in the dark at RT. Cells were 
washed with 1xPBT (w/v) for 30 min at RT, and 1xPBS (w/v) wash once. Cells were 
mounted with 1xPBS including Hoechst (4µg/ml) (Sigma, Cat. No. B2261).  
4.2.7. Microscopy and image analyses  
Cells were analysed by the epifluorescence microscope, Eclipse 80i (Nikon Instruments 
Inc., USA). Images were captured by the camera, CoolSnap cf (Photometrics, AZ., 
USA), and analysed by Image-Pro Plus version 5.0 (Media Cybernetics, Inc., MD., 
USA). Images were taken using the same UV power and by the same settings, as 
mentioned on section 2.5. Original images without further image adjustments were used 
to analyse. Experiments were performed as at least 3 independent replicates.  
4.2.8. Statistics 
The level of staining and the number of foci within the nucleus were compared using 
univariate analysis of variance (UNIANOVA). The level of staining is optical density 
(arbitrary units). The comparison between two groups were performed using post-hoc 
test. The staining pattern of antigens within the nuclei (as focal or diffuse staining) was 
compared using logistic regression analyses. Error bars represent +/- standard error of 
the mean (s.e.m).   
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4.3. RESULTS 
 
4.3.1. The antigenic retrieval of 5meC staining 
 
Trypsin treatment following acid treatment revealed a significant (p<0.0001) increase in 
the detection of total amount of 5meC staining, compared to acid treatment alone in 
confluent MEFs (Figure 4-1A and B). Cells treated with neither acid nor trypsin showed 
undetectable 5meC staining (Figure 4-1A). Subjectively, cells were classified as 
showing either a diffuse or focal pattern of 5meC staining. A diffuse distribution of 
5meC within the nuclei was referred to as ‘diffuse staining’ (arrowed nuclei, Figure 
4-1A), distinct 5meC foci structures throughout nuclei were referred to as ‘focal 
staining’. The proportion of nuclei showing a predominantly focal pattern of 5meC 
staining (nuclei without arrows in Figure 4-1A) was significantly higher (p<0.01) after 
trypsin treatment, compared to acid treatment alone (Figure 4-1A and C).  
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Figure 4-1. The pattern of nuclear 5meC staining after trypsin treatment in confluent 
MEFs by immunofluorescence. 
Confluent MEFs were fixed and permeabilized, and were treated with HCl for 0 min 
(No treatment) or 10 min (HCl), or HCl followed by brief tryptic digestion (HCl + 
trypsin). Cells were stained with 5meC. (A) Staining pattern for 5meC and non-immune 
IgG control is shown. Nuclei with a predominantly diffuse or focal pattern 5meC 
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staining are indicated with or without arrows, respectively. (B) Graphical comparison 
of the total 5meC staining. (C) Proportion of nuclei with focal 5meC staining is shown. 
Graphs represent (B) the total amount of 5meC staining, and (C) the total proportion of 
nuclei with focal 5meC staining, from at least three independent replicates. At least 110 
nuclei analysed per treatment in each replicate. Scale bar: 10 micron  and n, total 
number of nuclei analysed. ** p<0.01, **** p<0.0001 
 
The effect of changing the duration of HCl plus trypsin treatment on the detection of 
5meC was assessed (Figure 4-2). Permeabilized cells were treated with HCl for 0, 10 or 
20 min, followed by trypsin either for 0, 1 or 2 min. Representative images of the range 
of staining after each of these treatments are shown in Figure 4-2A. After 10 or 20 min 
HCl further treatment with trypsin for 1 or 2 min resulted a higher level of 5meC 
staining and a more consistent pattern of focal staining after trypsin treatment (Figure 
4-2A). There was no detectable 5meC staining in the absence of HCl treatment even 
after trypsin treatment (Figure 4-2B). Quantitative measurement of nuclear 5meC 
staining showed that longer acid treatment resulted in a similar pattern but significant 
reduction in total staining ((p<0.0001), Figure 4-2C). Trypsin had relatively small 
effects on total staining levels, with 1 min trypsin after 10 min acid giving a significant 
increase in staining levels, while longer trypsin treatments caused a reduction in the 
staining level. The major effect of trypsin treatment was the revelation of a consistent 
underlying focal pattern of 5meC staining. Increased acid treatment caused a small 
overall increase (p<0.0001) in the proportion of cells that displayed a predominantly 
focal pattern of staining while increased tryptic digestion caused a further marked 
increase in the detection of this pattern (p<0.0001) (Figure 4-2D).  
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Figure 4-2. The effect of duration of HCl or/and trypsin treatment on antigen 
retrieval of 5meC in confluent MEFs  
Permeabilized cells were treated with HCl either for 0, 10 or 20 min, followed by 
trypsin either for 0, 1 or 2 min. Control cells were treated with trypsin alone either for 1 
or 2 min. After acidic and/or tryptic treatments, cells were stained for 5meC. (A) The 
patterns of 5meC staining and non-immune IgG control after acid and/or trypsin are 
shown. Arrows indicate the diffuse staining of 5meC. Scale bar: 10 micron. (B) Staining 
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of cells subjected to tryptic digestion for 1 or 2 min without and prior HCl treatment. C 
and D show the total amount of 5meC staining and the proportion of cells with focal 
5meC staining (%), respectively. P values are shown for the overall effect of trypsin and 
its interaction effect with acid in C and D. E shows the total number of nuclei analysed 
(n) from five independent replicates. At least 92 nuclei were analysed for each 
treatment per replicate. Graphs represent +/- standard error of the mean. ** p<0.01, 
**** p<0.0001 
 
The 5meC foci within the nuclei were further analysed to determine whether trypsin 
also influenced the detection of intra-nuclear distribution of 5meC foci. The number of 
5meC foci within nuclei was significantly increased by trypsin treatment (p<0.05), 
however; increased time of HCl treatment resulted in an overall decrease in the 5meC 
foci number within a nucleus (p<0.01) (Figure 4-3A). Longer HCl provided a 
significant (p<0.0001) increase in the average size (cross-sectional area) of 5meC foci 
and trypsin accentuated this (p<0.0001) (Figure 4-3B).  
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Figure 4-3. The effect of time of HCl and/or trypsin treatment on 
immunofluorescence detection of 5meC foci within nuclei of confluent MEFs . 
Confluent MEFs were treated with HCl either for 10 or 20 min followed by trypsin 
either for 0, 1 or 2 min. After acidic and/or tryptic treatments, cells were stained for 
5meC. (A) The numbers of 5meC foci/nuclei and (B) the area of 5meC foci/nuclei are 
shown. P values are shown for the overall effect of trypsin (p<0.05 in A, p<0.0001 in B) 
and its interaction effect with acid (p>0.05 in both A and B). Graphs represents mean 
+/- s.e.m of five independent replicates. At least 150 foci analysed per treatment in each 
replicate. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 
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4.3.2.  The antigenic retrieval of MBD1  
The MBD1 protein is reported to selectively bind 5meC (Badran et al., 2011) and is 
widely used as a proxy measure for 5meC (Morita et al., 2012). To provide an 
alternative measure of global patterns of 5meC localisation, MEFs were subjected to 
immunolocalisation of MBD1. Confluent cells were fixed, permeabilized and treated 
with HCl for 0 or 10 min. Cells were then treated with trypsin for 0, 1, 1.5, 2 or 2.5 min 
and stained for MBD1 antigen. No detectable staining was observed in the absence of 
HCl pre-treatment of cells. After HCl treatment staining across the nucleoplasm was 
observed and there were a relatively small number of large staining foci (blue arrows, 
Figure 4-4A) in many but not all cells (yellow arrow in Figure 4-4A). After tryptic 
digestion (1 min) the staining pattern changed with a large number of MBD1 foci 
becoming obvious in most cells (red arrows, Figure 4-4A). Moreover, trypsin treatment 
caused a significant increase (p<0.0001) in the intensity of MBD1 staining (Figure 
4-4B), and reduced the number of nuclei (p<0.01) with a diffuse staining pattern (Figure 
4-4C). After trypsin treatment for longer than 1 min the MBD1 staining level 
progressively decreased, but the staining pattern remained predominately focal (Figure 
4-4B and C). 
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Figure 4-4. The effect of increased trypsin treatment on the nuclear pattern of MBD1 
staining in confluent MEFs by immunofluorescence. 
Permeabilized cells were treated with HCl for 10, followed by trypsin either for 0, 1, 
1.5, 2 or 2.5 min. Cells were stained with MBD1 after treatment. (A) The range of 
nuclear MBD1 staining is shown. Blue and red arrows represent giant and small MBD1 
foci, respectively. Yellow arrow represents the diffuse pattern of MBD1 staining. Scale 
bar: 5 micron. Graphs show (B) the total amount of MBD1 staining and (C) the 
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proportion of nuclei with focal MBD1 staining (%). (D) Total number of nuclei 
analysed (n) is given for each treatment. At least 98 nuclei analysed per treatment in 
each replicate. Error bars represent +/- s.e.m of at least three independent replicates. * 
p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001  
 
4.3.3. The effect of cell growth status on detection of 5meC  
 
The effects of the proliferative status of MEFs on the localisation of 5meC within the 
nucleus were assessed by examining cells in three different growth states: proliferative 
(1 day culture), confluent (3 days culture), and quiescent (3 days culture followed by 
24h serum deprivation) as described in the chapter 2 (section 2.2, figure 2.1). The 
distribution of 5meC staining using conventional immunostaining methodology differed 
between cells (as described in the foregoing section). Cells were also examined in their 
first passage after isolation for primary culture (P1) and after more prolonged culture, 
passage 7 (P7).  
 
This relationship was examined further by comparing the level of trypsin-sensitive 
masking of focal staining in proliferative, confluent and quiescent cells after either one 
or seven passages. Tryptic digestion caused a significant increase in the level of 5meC 
staining in both P1 and P7 and this effect was greater in P7 treatments (p<0.0001) 
(Figure 4-5A and B). However, proliferative cells at P1 and P7 both had higher overall 
levels of 5meC staining than confluent (p<0.0001) and quiescent (p<0.0001) cells, 
irrespective of trypsin use (Figure 4-5B). Fewer proliferative cells displayed a 
predominantly focal pattern of staining compared to confluent and quiescent cells in 
both P1 and P7 cells in the absence of tryptic digestion (p<0.0001) (Figure 4-5A and C). 
After tryptic digestion there was an increase in the proportion of cells with 
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predominantly focal staining across all treatment groups except quiescent (P7) cells 
(p<0.0001) (Figure 4-5C). The results show that much of the 5meC staining within 
MEFs existed as intense foci scattered through the nuclei of MEFs. There were varying 
degrees of trypsin-sensitive masking of these foci and the extent of this masking varied 
with the growth conditions and passage number of cells. In actively dividing cells of 
low passage number less of the 5meC foci were solvent exposed after HCl-only pre-
treatment compared to other growth states tested, but this difference was to a large 
extent reversed by tryptic digestion of cells.  
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Figure 4-5. The pattern of cytosine methylation in different growth stages and 
passages of MEFs.  
Proliferative, confluent and quiescent cells either passages (i) 1 or (ii) 7 were stained 
with 5meC after 10 min acid and 1 min trypsin. A shows the range of 5meC staining of 
passage (i) 1 and (ii) 7 during cell growth. Scale bar 10 micron. B and C show the total 
amount of 5meC staining and the proportion of nuclei with focal 5meC staining, 
respectively. D shows the total number of nuclei analysed for each group. Graphs show 
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+/- s.e.m. The results are representative of three independent experiments. * p<0.05, ** 
p<0.01 and **** p<0.0001 
 
Hoechst 33342 (bisBenzimide) shows preferential staining within heterochromatic 
chromatin hence counterstaining with Hoechst allowed profiling of the co-localisation 
of 5meC and heterochromatin. Co-staining for 5meC and Hoechst revealed that after 
acid treatment alone 5meC focal staining in each growth state was predominantly co-
localised with Hoechst-intense foci (arrowheads in - trypsin, Figure 4-6A and B). After 
brief tryptic digestion the total number and intensity of 5meC foci increased and these 
foci also predominantly co-localised with Hoechst-intense foci (arrowheads in + trypsin, 
Figure 4-6A and B). Non-immune IgG staining was not detectable in each cell, 
represented in proliferative culture (Figure 4-6C). Tryptic digestion resulted in an 
increase (p<0.0001) in the number of Hoechst-intense foci that were decorated by anti-
5meC staining, and a decrease in the number which were not co-stained by anti-5meC 
(p<0.0001) (Figure 4-6D). The results show that focal staining of 5meC co-localises 
with Hoechst-rich DNA foci regardless of cell proliferation (p>0.05).  
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Figure 4-6. The pattern of co-staining for 5meC and Hoechst in proliferative and 
quiescent cells. 
A and B show both individual and co-staining of 5meC and DNA stain (Hoechst) after 
acid alone or acid followed by trypsin in proliferative and  quiescent cells, respectively. 
C shows representative images for non-immune IgG control staining in proliferative 
cells. 5meC foci are co-localised with Hoechst-dense regions in each cell (represented 
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by arrowheads). D shows the number of Hoechst-dense regions per cell co-stained with 
5meC or not in both cells. Scale bar 10 micron. At least 80 foci were analysed for each 
treatment per replicate. Graph shows +/- s.e.m. The results are representative of three 
independent experiments. * p<0.05, **** p<0.0001 
 
Hoechst-intense staining of chromatin is commonly associated with heterochromatic 
regions of the nucleoplasm. The protein HP1-β is widely used as a marker of 
heterochromatin (Festenstein et al., 2003; Grigoryev et al., 2004; Lomberk et al., 2006) 
so it was examined whether the Hoechst-intense foci co-stained for HP1-β in each 
growth state (Figure 4-7). Staining for this protein was not compatible with tryptic 
digestion since proteolytic enzymes can catalyse the hydrolysis of the proteins 
(Karamac et al., 2002; Marques et al., 2011; Pecquet et al., 2000). Therefore, cells were 
assessed after acid-based antigen retrieval only. Figure 4-7A shows staining of HP-1β 
displayed a predominantly focal pattern. These foci co-localised with the Hoechst-
intense foci in MEFs under each growth condition (represented by arrowheads in Figure 
4-7A). The majority of Hoechst-intense foci in both proliferative and quiescent cells 
were decorated by the heterochromatin marker, HP1-β, and this co-staining of HP1-β 
and Hoechst-rich regions was similar in both proliferative and quiescent cells (p>0.05) 
(Figure 4-7B).  
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Figure 4-7. The pattern of co-staining for HP1-β and Hoechst in proliferative and 
quiescent cells. 
A shows both individual and co-staining of HP1-β and DNA stain (Hoechst) in 
proliferative and quiescent cells. Co-staining is represented by arrowheads. 
Representative non-immune IgG control staining is also shown for quiescent cells. 
Scale bar 10 micron. Graph (B) shows the number of Hoechst-dense regions co-stained 
with HP1-β or not in both cells. The number of Hoechst-foci co-localised with HP1-β is 
higher than the number of foci not co-stained with HP1-β. HP1-β co-localised with 
Hoechst foci irrespective of cell proliferation (p>0.05). At least 99 foci were analysed 
for each treatment per replicate. Graph shows +/- s.e.m. The results are representative 
of three independent experiments. ** p<0.01  
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Immunolocalisation of MBD1 showed different patterns of staining in proliferative and 
quiescent cells and also a difference after brief tryptic digestion. Staining persisted even 
after only acidic treatment (10 min) of cells (Figure 4-8A and B). Undetectable non-
immune IgG staining of cells is represented in proliferative cells (Figure 4-8C). In 
proliferative cells MBD1 staining was predominantly as a small number of large MBD1 
staining regions. These generally did not co-localise with the more numerous and 
smaller Hoechst-intense foci (green arrowheads, Figure 4-8A). In quiescent cells 
staining was more diffuse with some regionalised areas of more intense staining (yellow 
arrowheads, Figure 4-8B). Again, the staining did not predominantly co-localise with 
Hoechst-intense foci (Figure 4-8B). Tryptic digestion for 1 min resulted in an increase 
in the extent of diffuse staining in both proliferative and quiescent cells. Some of this 
increased staining co-localised with Hoechst-intense foci (white arrowheads, Figure 
4-8A and B). Numerical analysis showed that with tryptic-digestion the number of 
Hoechst-foci being decorated by MBD1 was significantly increased (p<0.0001) and this 
increased co-localisation was also affected by cell proliferation (p<0.001) (Figure 
4-8D). Thus, MBD1 forms two distinct immunodetectable populations within intact 
cells; one of which is solvent exposed after acid treatment, was not primarily associated 
with Hoechst foci, and was trypsin-sensitive; and another pool that became solvent 
exposed only after trypsin treatment, and was primarily co-localised with some 
Hoechst-intense foci. To assess whether MBD1 was always associated with 5meC co-
staining for 5meC and MBD1 was next performed.  
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Figure 4-8. The pattern of co-staining for MBD1 and Hoechst in proliferative and 
quiescent cells. 
A shows co-staining for MBD1 and DNA stain (Hoechst) in (A) proliferative and (B) 
quiescent cells and also (C) representative images for non-immune IgG control staining 
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in proliferative cells. Staining was performed either using acid alone or acid followed 
by trypsin. (i) Green, (ii) yellow and (iii) white arrowheads represent: (i) different 
localised MBD1 foci than Hoechst foci, (ii) diffuse staining of MBD1 and (iii) MBD1 
foci co-localised with Hoechst-dense regions. Scale bar 10 micron. Graph (D) shows 
the number of Hoechst foci co-stained with MBD1 or not. At least 114 foci were 
analysed for each treatment per replicate. Graph shows +/- s.e.m. The results are 
representative of three independent experiments. * p<0.05, *** p<0.001, **** 
p<0.0001 
 
The extent of MBD1 antigen and 5meC co-localisation was assessed in proliferative and 
quiescent cells (Figure 4-9). The levels of MBD1 and 5meC were positively correlated 
in both cells, and this was observed even after trypsin treatment (Figure 4-9A). The 
increase in the amount of both antigens suggests that 5meC is not entirely masked by 
MBD1, and MBD1 may bind to 5meC-free regions of the genome. Triple staining of 
5meC, MBD1 and DNA (Hoechst) showed that in the absence of tryptic digestion most 
of the Hoechst-intense foci co-stained with 5meC but not MBD1 (staining -/+) (Figure 
4-9B). After tryptic digestion, this pattern changed with the majority of Hoechst-intense 
foci co-decorated with both anti-5meC and anti-MBD1 (staining +/+) (Figure 4-9B). A 
significant minority of these Hoechst foci, however, were still decorated by anti-5meC 
but not MBD1 (staining -/+) (Figure 4-9B). In both cells, distinct MBD1 staining was 
again observed in giant foci structures before trypsin (yellow arrows), but this changed 
to smaller MBD1 foci detected after trypsin (white arrows) (Figure 4-10A,B). Staining -
/+ and staining +/+ are represented by blue and pink arrows in Figure 4-10A,B. These 
results demonstrate an unexpected heterogeneity in staining and indicate that MBD1 
analysis is not an entirely reliable proxy for 5meC measurement.   
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Figure 4-9. The nuclear staining patterns of 5meC and MBD1 during cell 
proliferation.  
Proliferative and quiescent (24h serum-starved confluent cells) MEFs were treated with 
10 min HCl followed by 1 min trypsin. Cells were then co-stained for 5meC and MBD1. 
The positive association between the levels of 5meC and MBD1 staining was shown for 
each cell (A). B shows the numbers of Hoechst-dense regions of DNA with different 
staining defined as MBD1 (stained +, not-stained -) and 5meC (stained +,not-stained -). 
Those patterns are significantly different from each other (p<0.0001). C shows the 
comparison of those staining patterns by Post-Hoc test. Graph shows +/- s.e.m. The 
results are representative of three independent experiments.(n total number of nuclei 
analysed and, nf total number of Hoechst-rich foci analysed) 
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Figure 4-10. Nuclear localisation of 5meC and MBD1 during cell proliferation.  
A and B show the localisation of 5meC and MBD1 proteins within the same nucleus in 
proliferative and quiescent cells, respectively. (i) Yellow, (ii) blue, (iii) white and (iv) 
pink arrowheads represent (i) large regions of MBD1 staining, (ii) different 5meC and 
MBD1 localisation, (iii) small regions of MBD1 foci and (iv) Hoechst-intense co-
stained for both MBD1 and 5meC. Scale bar 10 micron. 
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4.4. DISCUSSION 
 
This chapter shows that use of conventional acid-induced denaturation of chromatin 
does not result in the solvent exposure of a pool of 5meC in MEFs. Further treatment of 
fixed cells by brief tryptic digestion was required to recover this pool of 5meC, and 
much of this was present as staining-intense foci. Based on the Hoechst-intense nature 
of these regions and their co-staining with HP1-β it is considered that these foci are 
associated with heterochromatin. The study also showed that the amount of trypsin-
sensitive 5meC varied with the proliferative status of cells. More of the heterochromatin 
associated 5meC was masked in a trypsin-sensitive manner in proliferative cells, and 
this level was reduced as cells withdrawn from the cell-cycle in confluence and 
quiescence. Aged cells are reported to progressively loose DNA methylation 
(Thompson et al., 2010), yet this analysis showed an overall increase in the level of 
5meC staining in aged (P7) cells compared to younger (P1) cells. It is known that 
hypermethylation of CpG islands occurs with age. By contrast, non-island CpGs tend to 
become hypomethylated (Christensen et al., 2009). But the work reported here does not 
allow discrimination at the base level and therefore provides no new insight into this 
question.  
This study shows that the use of the widely accepted technique for global staining of 
5meC that uses acid-induced denaturation only, can provide a picture of large changes 
in the global levels and pattern of 5meC stain that are artefactual. This results from 
changes in the extent of trypsin-sensitive masking of the antigen. This infers that the 
solvent exposure of 5meC varies greatly depending upon nuclear conformation and/or 
structure and show that these changes should not be taken as evidence of acute changes 
in the total level of nuclear 5meC. 
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This observation of trypsin-sensitive masking of MEFs is similar to the that observed in 
the early embryo (Li and O'Neill, 2012). It was found that long-standing reports of 
global loss of 5meC following fertilisation  (Hatanaka et al., 2013; Iqbal et al., 2011; 
Wossidlo et al., 2011) were accounted for by a progressive onset of trypsin-sensitive 
masking of the antigen during zygotic maturation (Li and O'Neill, 2012). It is 
noteworthy that in the embryo MBD1 staining after acid-treatment showed the same 
pattern as 5meC staining after acid plus trypsin treatment (Li and O'Neill, 2012), but 
this was not found to be the case in this analysis of MEFs.  
MBD1 staining of MEFs after acid treatment alone showed a different pattern of 
localisation than expected if it was a reliable marker of 5meC. After brief tryptic 
digestion, however, the MBD1 and 5meC staining patterns became more similar, 
although not identical. The observation that much of the MBD1 staining in acid-only 
treated cells did not co-localise with 5meC and the further observations in acid plus 
trypsin treated cells that some 5meC did not co-localise with MBD1 points to the need 
for caution in the use of this protein as a proxy measure for 5meC. The molecular 
causes of these differences were not explored in this study and warrant further 
investigation. However, it is known that MBD1 also exists in euchromatin and can 
associate with some regions of transcriptional silencing within euchromatin (Fujita et 
al., 1999). Tryptic digestion may have different impacts on the accessibility by 
antibodies to the differing regions of chromatin. Therefore, antigenicity may depend on 
the trypsin sensitivity of different proteins which bind to MBD1 within heterochromatin 
or euchromatin. This question requires further experimental investigation.  
This chapter shows that the trypsin-sensitive masking of 5meC that was first discovered 
to occur during zygotic maturation (Li and O'Neill, 2012) can also occur in a 
differentiated somatic cell, such as fibroblasts. The extent of this masking varied greatly 
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between individual cells and under different growth conditions of the same lineage. 
Masking was most severe in young cells (P1) that were proliferating. Even under these 
conditions, however, the extent of masking was not as great as that observed in the 
zygote (Li and O'Neill, 2012). The results confirm that acute changes in the levels of 
5meC detected using conventional methods of immunolocalisation cannot be taken as 
evidence of changes in global methylation levels without extensive further validation 
and experimental support.  
Although 5meC lies within the major groove of DNA (Vargason et al., 2000), the 
extensive coiling and compaction of DNA means that 5meC is not accessible to 
antibodies in chromatin’s native state. While acid-induced denaturation has been the 
standard method for immunolocalisation for a couple of decades, there has been only 
limited systematic analysis of the conditions required to reliably recover the 5meC 
epitope under all conditions. The structure and conformation of chromatin is known to 
dynamically change with the growth status of cells (Bridger et al., 2000; Grigoryev et 
al., 2004; Santos et al., 2005). Heterochromatin is the highly compacted region of the 
genome, and the enrichment of 5meC in these regions (Akhmanova et al., 2000; 
Hajkova et al., 2008; Wongtawan et al., 2011) makes it hardly surprising that the 
epitope showed high levels of masking.  
Heterochromatin is characterised by an increase in the intensity of staining with dyes 
such as Hoechst and is typically associated with binding of HP1-β. The cell-cycle and 
the ontological state of cells influence the pattern of heterochromatin formation 
(Eissenberg and Elgin, 2005; Martin et al., 2006). Histone modifications also play roles 
in heterochromatin formation (Peixoto et al., 2012; Wongtawan et al., 2011; Woodcock 
and Ghosh, 2010) and histone localisation depends on cell-cycle and the changes in 
DNA methylation (Peixoto et al., 2012; Sugimura et al., 2010). Cytosine methylation is 
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known to be a major determinant of the recruitment of DNA to heterochromatin 
(Akhmanova et al., 2000; Hajkova et al., 2008; Kang et al., 2001; Wongtawan et al., 
2011) and DNA methylation is commonly used as a heterochromatin mark (Fazzio and 
Panning, 2010; Wongtawan et al., 2011). Heterochromatic foci (also known as 
chromocenters) are typically enriched for pericentric heterochromatin (Martin et al., 
2006). These sites are also typically enriched with a range of repressive histone 
modifications (Lehnertz et al., 2003) that act with 5meC to create transcriptionally 
repressive chromatic state (Hajkova et al., 2008).  
Immunolocalisation is a valuable technique for the analysis of relative changes in the 
patterns and distribution of an antigen. It is not, however, a strictly quantitative tool and 
the results of this chapter should not be considered to provide a measure of the total 
5meC levels within a cell. They provide a measure of the total solvent exposed antigen 
with the techniques used. The study shows that the levels and localisation of these 
solvent exposed components can vary greatly with the growth status of the cell and the 
manner of preparation of the cell for staining. The study confirms the need for both acid 
and trypsin treatment to maximise the retrieval of this epitope, but this does not of itself 
prove that the retrieval is entirely complete. It is possible that other pools of 5meC may 
still exist within the cell’s chromatin. Taking these potential limitations into account the 
techniques optimised here provide new insights into the effects of nuclear structure and 
architecture on the solvent exposure of 5meC in normal cells.  
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5. CHAPTER 5: THE EFFECTS OF DNA DAMAGE ON THE 
LOCALISATION OF 5meC IN MEFs  
5.1. INTRODUCTION 
Current models implicate potential roles for DNA repair-related processes in active 
cytosine demethylation (Cortazar et al., 2011; Cortellino et al., 2011; Guo et al., 2011; 
Tahiliani et al., 2009). DNA repair processes commonly involve reduced chromatin 
compaction and heterochromatin expansion, and this allows repair factors to access 
DNA damaged sites (Baldeyron et al., 2011; Terzoudi et al., 2011). In the previous 
chapter it was shown that much 5meC was associated with heterochromatin and this 
was masked in a trypsin-sensitive manner. Given the possible roles of the DNA-damage 
response on the conformation of heterochromatin, in this chapter the effects of various 
forms of genotoxic stress on the levels of solvent exposure and trypsin-sensitive 
masking of 5meC are assessed.  
The genotoxic stressors used are UV-irradiation and a DNA-intercalating drug, 
doxorubicin.  Exposure to UV can induce single strand DNA breaks (SSBs) (Loignon 
and Drobetsky, 2002; Mone et al., 2001), and doxorubicin causes double strand DNA 
breaks (DSBs) (Kothapalli et al., 2005; L'Ecuyer et al., 2006). This chapter identified 
the conditions required for induction of DNA damage by these treatments and then 
assessed the effects of the damage caused on the detection of solvent exposed 5meC.  
  
99 
 
5.2. MATERIAL AND METHODS 
 
5.2.1.  UV irradiation and post-incubation  
Quiescent MEFs were exposed to UV-irradiation either for (i) 12 min or (ii) 15 sec 
followed by post-incubation either for (i) 1h (in serum-free media) or (ii) 48h (in 
complete media). Exposure was via a UV lamp (253.7nm at a dose of 1.95J/cm
2
). Cells 
were in HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffered media 
(pH 7.4) (Invitrogen, Cat. No. 12430) at 37°C, during exposure. HEPES-buffered media 
included bovine serum albumin (BSA) (3mg/ml). Control cells were untreated at 37°C 
with 5%CO2 in air. 
5.2.2.  Doxorubicin treatment 
Proliferative MEFs were treated with doxorubicin (Sigma, Cat. No. D1515) at doses of 
0 or 50 nM in complete media for 24h.  
5.2.3.  Cell-cycle analysis 
After treatment, cells were washed with 1xDPBS (Invitrogen; Cat. No. 14190-144) (Ca 
2+
, Mg 
2+
 free, and pre-warmed to 37°C before use) and detached by 0.25% trypsin-
EDTA (Invitrogen; Cat. No. 25200-56) for up to 5 min. Trypsin was inactivated with an 
equal volume of complete media and removed by 4 min centrifugation at 400g. Cells 
were washed in 1xPBS, and then incubated in the dark with Propidium iodide (PI) 
(Sigma; Cat. No. P4170) in 2% triton-x/PBS (v/v) (final concentration 50mM) for 30 
min at RT. DNA mass in G1/0, S and G2/M phases was analysed by fluorescence 
channel-2 (FL2-A) of flow cytometry instrument (BD FACSCalibr, BDIS San Jose Ca. 
USA). The analysis of DNA mass over the cycle is based on DNA content in the cells. 
Cell populations were analysed using BD CellQuest
TM 
Pro software (BD FACSCalibr, 
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BDIS San Jose Ca. USA). Dot plots and histograms were made using BD CellQuest
TM 
Pro software.  
5.2.4.  Cell viability 
After treatment, cells were washed with 1xDPBS and detached by 0.25% trypsin-EDTA 
for up to 5 min. Trypsin was inactivated with an equal volume of complete media and 
removed by 4 min centrifugation at 400g. Cells were washed in 1xPBS, and then 
incubated in trypan blue (TB) solution (0.4%) (Sigma, Cat. No. T8154) for 10 min at 
RT. Cells excluding or staining with TB were counted using haemocytometer.  
5.2.5.  Immunofluorescence for γ-H2A.X (phosphoS139) 
The phosphorylated form of the H2AX histone variant (γ-H2A.X) co-localises with 
repair proteins, such as Rad50 and Rad51, at DNA breaks (Mah et al., 2010; Oh et al., 
2011; Redon et al., 2010) and its localisation is commonly used as a marker of DNA 
damage.  
After treatment, MEFs were washed with 1xPBS and fixed with 2% (w/v) PFA (Sigma, 
Cat. No. P6148) for 30 min at RT. Cells were permeabilized with 2%PFA containing 
0.3% (v/v) tween-20 (Sigma, Cat. No. P7949) and 0.2% (v/v) triton-x (Bio-Rad 
Laboratories Inc., CA, USA, Cat. No.161-0407) for 30 min at RT. Cells were washed in 
1xPBS (w/v) (Sigma, Cat. No. D5773) for 30 min followed by blocking in 30% (v/v) 
goat serum (Sigma, Cat. No. G9023) in 2 mg/ml BSA in PBS with 0.05% triton-x (w/v) 
(BSA, from Sigma, Cat. No. A1470) for 3h at RT. Cells were washed in 1xPBS for 30 
min at RT. Cells were incubated in primary antibodies (1:250): rabbit polyclonal anti-
gamma(γ)-H2A.X (phosphoS139) (Abcam, UK; Cat. No. ab2893) to detect DNA 
damage; or a non-immune rabbit IgG (Sigma, Cat. No.I5006) in 2 mg/ml BSA in PBS 
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with 0.05% triton-x (w/v) at 4°C overnight. Cells were washed in 1xPBS for 30 min, 
and then were incubated with a fluorescein-conjugated secondary antibody, FITC 
(1:200) (Sigma, Cat No.F1262) in 2 mg/ml BSA in PBS with 0.05% triton-x (w/v) for 
1h at RT in the dark. Cells were washed in 1xPBS for 30 min, and then mounted with 
1xPBS. 
5.2.6. Immunofluorescence for double staining of 5meC and MBD1  
After treatment, MEFs were washed with 1xPBS (w/v) and fixed with 4 % (v/w) PFA 
for 30 min at RT. Cells were washed with 1xPBT (w/v) for 30 min. Cells were 
permeabilized with 1xPBS including 0.5% (v/v) triton-x and 0.5% (v/v) tween-20 for 40 
min at RT. Cells were treated with 4N HCl containing 0.1% (v/v) triton-x for 10 min at 
RT. Acid was removed by extensive washing with 1xPBT. Cells were treated with 
trypsin (0.25%) either for 0 or 1 min at 37°C. Trypsin was inactivated with the equal 
volume of pre-warmed media including 90% (v/v) DMEM, 3 mg/ml BSA and 10% 
(v/v) sheep serum, for 1 min at 37°C. Cells were incubated with deactivation media for 
2 min at 37°C. Cells were washed with 1xPBT (w/v) followed by blocking in serum 
mix containing 10% (v/v) goat and 30% (v/v) sheep serum in 1xPBT at 4°C overnight. 
Cells were incubated in primary antibodies: rabbit anti-MBD1 (1:50) or non-immune 
rabbit IgG (1:50) in 2 mg/ml BSA in 1xPBT overnight at 4°C. Cells were washed with 
1xPBT for 10 min at RT followed by incubation with primary antibodies: mouse anti-
5meC (1:60) or non-immune mouse IgG (1:60) in 2 mg/ml BSA in 1xPBT for 1h at RT. 
Cells were washed with 1xPBT (w/v) for 30 min. Cells then were incubated with 
secondary antibody mix including anti rabbit-Texas Red (1:200) and anti mouse-FITC 
(1:200) in 2 mg/ml BSA in 1xPBT (w/v) for 1h in the dark at RT. Cells were washed 
with 1xPBT (w/v) for 30 min at RT. Cells were mounted with 1xPBS including Hoechst 
(4µg/ml).  
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5.2.7. Immunofluorescence for double staining of MBD1 and HP1-β 
After treatment, MEFs were washed with 1xPBS (w/v) and fixed with 4 % (v/w) PFA 
for 30 min at RT. Cells were washed with 1xPBT (w/v) for 30 min. Cells were 
permeabilized with 1xPBS including 0.5% (v/v) triton-x and 0.5% (v/v) tween-20 for 40 
min at RT. Cells were treated with 4N HCl containing 0.1% (v/v) triton-x for 10 min at 
RT. Cells were washed with 1xPBT (w/v) for 30 min at RT followed by two-step 
blocking: (i) in 30% (v/v) goat serum in 1xPBT at 4°C overnight, and then (ii) 30% 
(v/v) sheep serum in 1xPBS for 2h at RT. Cells were incubated in primary antibody 
mixes including either rabbit anti-MBD1 (1:50) (Abcam, Cat. No. ab3753) and mouse 
anti-HP1-β (1:200) (Abcam, Cat. No. ab101425), or non-immune rabbit IgG (1:50) 
(Sigma, Cat. No. I5006) and mouse IgG (1:200) (Sigma; Cat. No. M7894) in 2 mg/ml 
BSA in 1xPBT (w/v) at 4°C overnight. Cells were washed with 1xPBT (w/v) for 30 min 
at RT. Cells then were incubated with secondary antibody mix including anti rabbit-
Texas Red (1:200) (Abcam, Cat. No. ab6719) and anti mouse-FITC (1:200) (Sigma, 
Cat. No. 6257) in 2 mg/ml BSA in 1xPBT (w/v) for 1h in the dark at RT. Cells were 
washed with 1xPBT (w/v) for 30 min at RT, and 1xPBS (w/v) wash once. Cells were 
mounted with 1xPBS including Hoechst (4µg/ml).  
5.2.8. Microscopy and image analyses 
Microscopy and image settings were the same as described on section 2.5. At least 89 
nuclei were analysed for the total staining amount of antigens and at least 57 foci were 
analysed for the characteristics of focal staining in each treatment per replicate. The 
pattern of γ-H2A.X was determined as (i) the number of nuclei stained with γ-H2A.X in 
each treatment and/or (ii) the total amount of γ-H2A.X staining with at least 100 nuclei 
per treatment. 
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5.2.9. Statistics 
Statistical analyses were performed by SPSS program, version 19. Graphs were made 
using SPSS. The total amount of 5meC staining and the numbers of 5meC foci within 
the nuclei were analysed using UNIANOVA. The percentages of cells in cell-cycle 
checkpoints and the percentages of viable cells were arcsine-transformed, and compared 
using UNIANOVA. Differences between groups were determined by post-hoc test. The 
proportions of nuclei stained with antigens were compared using binary logistic 
regression analysis. The relationship between 5meC and MBD1 in a nucleus was 
analysed by linear regression. 
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5.3. RESULTS 
 
5.3.1. Establishment of experimental models for DNA damage 
5.3.1.1. Development of a model of acute DNA damage by UV-irradiation (Model 
1) 
The aim of this model was to induce significant DNA damage at 1 h after exposure to 
UV-irradiation. Quiescent MEFs were treated with UV for 12 min and examined at 1h 
after UV. Control cells were untreated. Cell-cycle analyses showed that there was no 
significant effect of UV treatment on the number of cells arrested at checkpoints (G1/0 
or G2/M) at this time compared to untreated control cells (p>0.05) (Figure 5-1A-D). 
However; UV treatment induced an increase (p<0.0001) in the number of nuclei with γ-
H2A.X staining (Figure 5-2A and B). Only a small number of nuclei were stained in 
untreated control MEFs (Figure 5-2A). The pattern of γ-H2A.X nuclear staining is 
shown in Figure 5-2B. It is concluded that UV-irradiation for 12 min caused a 
significant level of DNA damage 1h after treatment, compared to untreated controls, 
and this was adopted as a model for assessing the immediate effects of DNA damage on 
localisation of 5meC. Model 1 - 12 min UV of quiescent MEFs and their analysis 1h 
later. 
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Figure 5-1. Cell-cycle analyses of quiescent MEFs at 1h after 12 min UV.  
UV treated for 0 or 12 min, then incubated with Propidium iodide (PI) for 30 min at 1h 
after UV. A and B show the proportion of cells (%) arrested at G1/0 and G2/M 
checkpoints, respectively. UV treatment did not cause a significant difference in the 
number of cells either at G1/0 or G2/M (p>0.05). C shows the gated population of cells 
(green, gate 1) and D shows the representative count of a gated population at cell-
cycle. Graphs represent mean +/- s.e.m of at least three independent replicates. At least 
10,000 total events were acquired for each treatment per replicate.  
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Figure 5-2. γ-H2A.X (phosphoS139) nuclear staining at 1h after 12 min UV in 
quiescent MEFs.  
Quiescent MEFs were treated with UV for 12 min. Cells were fixed at 1h after UV and 
stained with γ-H2A.X (phosphoS139) antibody. (A) The proportion of nuclei (%) with 
H2A.X staining and (B) the nuclear pattern of γ-H2A.X staining are shown. UV 
significantly induced γ-H2A.X phosphorylation, however; a few numbers of nuclei were 
stained in untreated cells. Phase: 40X, and scale bar: 5 micron. At least 210 nuclei 
were analysed per treatment from at least three independent replicates. Graph 
represent +/- s.e.m. of at least three independent replicates. (n, total number of nuclei 
analysed). 
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5.3.1.2. Development of a model for effects of DNA damage long after UV-
irradiation (Model 2) 
This model aimed to find a dose of UV that induced DNA damage yet allowed cells to 
survive for several days after treatment. Quiescent MEFs were exposed to UV for 0, 15, 
30, 60 sec and then cultured for 3, 24 or 48h. Cell survival declined over 48h culture for 
UV exposure periods greater than 15 sec (p<0.05) (Figure 5-3). In agreement with this 
result, the proportion of cells (%) arrested at G1/0 or G2/M was not different at 48h 
after UV (15sec) compared to untreated cells (p>0.05) (Figure 5-4A-D). However, these 
cells still showed a significant accumulation (p<0.0001) of γH2A.X after 48h culture 
(Figure 5-5A and B) and the proportion of nuclei (%) stained with γ-H2A.X after 48h 
culture was significantly (p<0.0001) increased by 15 sec UV exposure, compared to 
untreated control cells (Figure 5-5C). These results show that UV exposure for as short 
as 15 sec caused DNA damage, some of which persisted (assessed by accumulation of 
γH2AX) for 48h. This was not sufficient to cause loss of cell viability over 48h. Model 
2 - quiescent MEFs treated for 15sec UV and cultured for up to 48h. 
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Figure 5-3. The proportion of viable cells (%) at 3, 24, 48h after UV (0, 15, 30, 60 sec) 
in quiescent MEFs.  
Quiescent MEFs were treated by UV either for 0, 15, 30 or 60 sec. Cells were incubated 
with trypan blue (TB) dye either at 3, 24 or 48h after UV. Stained and unstained cells by 
TB were counted after 10 min. Graphical comparisons for % of viable cells (%) are 
shown. Graphs represent mean +/- s.e.m of at least three independent replicates.* 
p<0.05 
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Figure 5-4. Cell-cycle analyses of quiescent MEFs at 48h after 15 sec UV.  
UV treatment for 0 or 15 sec then cultured for 48h. Cells stained with PI. A and B show 
the proportion of cells (%) arrested at G1/0 and G2/M checkpoints, respectively. UV 
treatment did not cause a significant difference in the number of cells either at G1/0 or 
G2/M (p>0.05) compared to untreated cells. C shows the gated population of cells 
(green, gate 1) and D shows the representative counts of a gated population at cell-
cycle. Graphs represent mean +/- s.e.m of at least three independent replicates. At least 
10,000 total events were acquired for each treatment per replicate.  
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Figure 5-5. γ-H2A.X (phosphoS139) nuclear staining at 48h after 15sec UV in 
quiescent MEFs.  
Quiescent MEFs were treated with UV for 15 sec. Cells were fixed at 48h after UV and 
stained with γ-H2A.X (phosphoS139) antibody. Control cells were untreated. (A) The 
pattern of nuclear γ-H2A.X staining is shown. Scale bar: 10 micron. (B) Total amount 
of γ-H2A.X staining and (C) the proportion of nuclei (%) with γ-H2A.X staining are 
shown. Graphs show +/- s.e.m of at least three independent replicates. At least 200 
nuclei were analysed per treatment in each replicate. **** p<0.0001. (n, total number 
of nuclei analysed) 
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5. 3.1.3. Development of DNA damage induced by doxorubicin (Model 3) 
Proliferative MEFs were treated with doxorubicin (0 or 50nM) and cell-cycle analyses 
performed by flow cytometry after 24h of treatment. Doxorubicin had no significant 
(p>0.05) effect on the proportion of cells that accumulated at G1/0 phase (Figure 5-6A), 
however, it increased the number of cells arrested at G2/M phase (p<0.05) (Figure 5-6B 
and D). There was no significant (p>0.05) arrest of the cell-cycle observed after 
doxorubicin treatment for longer incubations periods (48h and 72h) (Figure 5-7A and 
B). This may have resulted from a loss of biological activity of the drug with prolonged 
culture (Beijnen et al., 1986).  
DNA damage at 24h after doxorubicin treatment was then tested by γ-H2A.X staining. 
Since γH2A.X also appears in replicating DNA (Gagou et al., 2010) all nuclei showed a 
low level γ-H2A.X staining (Figure 5-8A and B). However, the level of γ-H2A.X 
staining was significantly (p<0.0001) higher in doxorubicin-treated cells (Figure 5-8B). 
These results show that prolonged term treatment of cells with doxorubicin induced 
DNA damage but allowed continued cell survival. Model 3 - doxorubicin (50nM) 
treatment of proliferative MEFs for 24h. 
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Figure 5-6. Cell-cycle analyses of proliferative MEFs at 24h after doxorubicin by 
flow cytometry.  
Doxorubicin (0 or 50nM) for 24h. Cells were incubated with PI for 30 min at 24h. A 
and B show the proportion of cells arrested at G1/0 and G2/M checkpoints, 
respectively. C shows the gated population of cells (green, gate 1) and D shows the 
representative counts of a gated population at cell-cycle. Graphs represent mean +/- 
s.e.m of at least three independent replicates. At least 10,000 total events were acquired 
for each treatment per replicate. * p<0.05 
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Figure 5-7. Cell-cycle analyses of proliferative MEFs at 48h and 72h after 
doxorubicin by flow cytometry.  
Proliferative MEFs were treated with doxorubicin (0 or 50nM) for 48 or 72h. Cells 
were incubated with PI for 30 min after doxorubicin. A and B show the representative 
counts of gated populations at cell-cycle after 48h and 72h, respectively. Doxorubicin 
did not affect arrest at either 48h or 72h (p>0.05). At least 10,000 total events were 
acquired for each treatment per replicate.  
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Figure 5-8. γ-H2A.X (phosphoS139) nuclear staining at 24h after doxorubicin in 
proliferative MEFs.   
Proliferative MEFs were treated doxorubicin (50nM) for 24h. Control cells were 
untreated. Cells were fixed at 24h after doxorubicin and stained with γ-H2A.X 
(phosphoS139) antibody. (A) The pattern of γ-H2A.X staining is shown. Scale bar: 10 
micron. (B) Total amount of γ-H2A.X staining was more in doxorubicin-treated cells 
than drug-free cells. Graph represents optical density (arbitrary units) mean +/- s.e.m 
of at least three independent replicates. At least 140 nuclei were analysed per treatment 
in each replicate. ****p<0.0001. (n, total number of nuclei analysed) 
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5.3.2. The pattern of DNA methylation after DNA damage  
5.3.2.1. Model 1 – The acute effects of UV-irradiation on detection of 5meC 
The effect of UV treatment on the level of HCl-sensitive and trypsin-sensitive 5meC 
and MBD1 detected within nuclei 1h after UV exposure was assessed (Figure 5-9). The 
HCl-sensitive pool of 5meC increased after UV (p<0.0001). After trypsin treatment the 
overall 5meC levels of both groups were higher (p<0.0001) but the level detected in UV 
treated cells was marginally lower (Figure 5-9A). MBD1 showed a different pattern, 
UV-treatment had no effect on the HCl-sensitive or trypsin-sensitive pools, but the 
overall levels detected were higher after trypsin treatment (Figure 5-9B). Some cells 
were co-stained for each of these antigens so direct comparison could be made. The 
scatter plots (Figure 5-9C and D) show that while the relationship between 5meC and 
MBD1 was similar after epitope retrieval by either acid or trypsin treatment in control 
cells, this was not the case for UV-treated cells. UV treatment caused more MBD1 
staining relative to the amount of 5meC detected.  
The results showed that UV increases the pool of detectable 5meC, but this study does 
not reveal whether the observed increase in staining detected after UV-treatment alone 
resulted from a hyper-methylation event or resulted from some change in chromatin 
conformation that resulted in an increase in solvent exposure of 5meC. Future studies 
will require this question to be addressed by a range of alternative methodologies 
capable of global measurement of total methylation levels. 
 
116 
 
 
Figure 5-9. The pattern of 5meC and MBD1 after UV (Model 1).  
A and B show the total amount of 5meC and MBD1, respectively. C and D show the 
correlation between the amount of 5meC and MBD1 in untreated and UV-treated cells, 
respectively. The numbers of nuclei analysed (n) and Pearson’s correlation coefficients 
are shown. Graphs represent optical density (arbitrary units) mean +/- s.e.m of at least 
three independent replicates. At least 100 nuclei were analysed per treatment in each 
replicate. **** p<0.0001 
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Analysis of individual nuclei showed that much of this extra MBD1 staining in UV-
treated cells was accounted for by an increased pattern of diffuse staining throughout 
the nucleoplasm and this was not predominantly associated with 5meC-staining (Figure 
5-10). MBD1 foci did not co-stain either with 5meC foci or Hoechst-rich foci 
(represented within the white boxes in Figure 5-10A-B). After trypsin treatment, a 
majority of MBD1 foci was co-stained with 5meC foci both in untreated and UV-treated 
cells (represented within the blue boxes in Figure 5-10A-B). This analysis also showed 
that the overall pattern of 5meC staining was similar in both UV-treated and untreated 
cells, and a low level of diffuse 5meC staining across the nucleoplasm with some 
5meC-intense foci (that corresponded to Hoechst-enrich staining) (Figure 5-10A-B). In 
UV-treated cells more of these 5meC-intense foci were detected without the necessity 
for trypsin treatment and this seemed to largely account for the marked increase in 
5meC staining level observed in these cell (Figure 5-10B).  
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Figure 5-10. Nuclear localisation of 5meC and MBD1 after UV treatment (Model 1).  
Nuclei are representative of Figure 5-9 for (A) untreated and (B) UV-treated MEFs. 
Scale bar 5 micron. White boxes represent different localisation of MBD1 foci than 
Hoechst and 5meC foci, and blue boxes represent the co-localisation of MBD1 foci with 
5meC foci. Trypsin showed this co-localisation of 5meC and MBD1 within DNA-rich 
foci which was not seen after acid alone.  
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5.3.2.2. Model 2 – The long-term effect of UV-irradiation on detection of DNA 
methylation 
 
A similar analysis was performed for the detection of the effect of UV on detection of 
DNA methylation at 48h after the genotoxic stress (Model 2). The level of both 5meC 
and MBD1 increased after trypsin treatment and were markedly higher after UV 
treatment (after both acid and trypsin treatment) (Figure 5-11A and B). This relative 
increase after UV, however, was in part due to a lower levels of staining than expected 
in untreated cells compare to that observed in cells not cultured (Figure 5-11A and B). 
In each treatment, the amount of MBD1 and 5meC antigen detected was again 
positively correlated and this was the case for both control and UV-treated cells 
(p<0.0001) (Figure 5-11C and D). 
Analysis of individual nuclei showed that in acid-treated control cells there was 
remarkably little staining observed across the nucleoplasm, while Hoechst staining 
showed an unexpected high level of focal, heterochromatic staining (Figure 5-12A). 
Trypsin treatment revealed a high level of focal 5meC staining associated with 
heterochromatin. UV treatment resulted in some of the focal 5meC in heterochromatin 
to be detected after acid treatment alone, but trypsin treatment increased the level of 
detection at these sites (Figure 5-12A-B). This analysis also showed that MBD1 foci did 
not co-localise either with 5meC or heterochromatin (represented within the  white 
boxes), but trypsin showed some co-localisation (represented within the  orange boxes) 
(Figure 5-12A, B). In all of these treatments there was only partial overlap between 
MBD1 and 5meC staining.  
These results show that prolonged culture of the cells under these condition caused 
increased heterochromatinization of cells (assessed by the focal pattern of Hoechst-
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staining). This was associated with a reduced level of detection of 5meC. After UV-
treatment the level of heterochromatin seemed to be reduced and some of the 5meC in 
the heterochromatic foci was more solvent exposed in the absence of trypsin treatment 
compared to control of cells.  
 
Figure 5-11. The pattern of 5meC and MBD1 after UV (Model 2).  
Double staining for 5meC and MBD1. A and B show the total amount of 5meC and 
MBD1, respectively. C and D show the correlation between the amount of 5meC and 
MBD1 in untreated and UV-treated cells, respectively. The number of nuclei analysed 
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and Pearson’s correlation coefficients are shown. Graphs represent optical density 
(arbitrary units) mean +/- s.e.m of at least three independent replicates. At least 80 
nuclei were analysed per treatment in each replicate. **** p<0.0001 
 
 
Figure 5-12. Nuclear localisation of 5meC and MBD1 after UV treatment (Model 2).  
Nuclei are representative of Figure 5-11 for (A) untreated and (B) UV-treated MEFs. 
Scale bar 5 micron. White boxes represent different localisation of MBD1 foci than 
Hoechst and 5meC foci, and orange boxes represent the co-localisation of MBD1 foci 
with 5meC foci. Trypsin showed this co-localisation of 5meC and MBD1 within DNA-
rich foci which was not seen after acid alone.  
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5.3.2.3. Model 3 – The pattern of DNA methylation staining after DNA damage 
induced by doxorubicin 
The level of both 5meC and MBD1 staining increased after trypsin treatment and both 
antigens were detected at significantly higher levels after doxorubicin treatment (after 
both and acid and trypsin treatment) (Figure 5-13A and B). In each treatment, the 
amount of MBD1 and 5meC was positively correlated and showed a similar association 
after trypsin treatment (Figure 5-13C and D). 
 
Analysis of the distribution of both antigens showed that there were considerable 
differences between the localisation of each (Figure 5-14A and B). After acid treatment 
alone MBD1 staining tended to be under-represented within the heterochromatic foci 
and over-represented in the rest of the nucleoplasm compared to 5meC staining (Figure 
5-14A). This difference was also observed after doxorubicin treatment (Figure 5-14B). 
5meC was predominantly represented as staining-intense foci. As was the case for UV-
treatment, doxorubicin increased the amount of solvent exposed 5meC detected after 
acid treatment only. This included the detection of some of the 5meC in 
heterochromatic foci. Trypsin treatment increased the overall level of 5meC and MBD1 
detected (Figure 5-14A and B). Trypsin also revealed co-localisation of MBD1 with 
5meC and Hoechst-rich foci (represented within the yellow boxes) which was not seen 
after acid treatment alone (represented within the white boxes) (Figure 5-14A and B).  
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Figure 5-13. The pattern of 5meC and MBD1 after doxorubicin (Model 3).  
 Double staining for 5meC and MBD1 was performed. A and B show the total amount of 
5meC and MBD1, respectively. C and D show the correlation between the amount of 
5meC and MBD1 in untreated and UV-treated cells, respectively. The number of nuclei 
analysed and Pearson’s correlation coefficients are shown. Graphs represents optical 
density (arbitrary units) mean +/- s.e.m of at least three independent replicates. At least 
100 nuclei were analysed per treatment in each replicate. **** p<0.0001  
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Figure 5-14. Nuclear localisation of 5meC and MBD1 after doxorubicin (Model 3). 
Nuclei shown are representative of Figure 5-13 for (A) untreated and (B) UV-treated 
MEFs. Scale bar 5 micron. White boxes represent different localisation of MBD1 foci 
than Hoechst and 5meC foci, and yellow boxes represent the co-localisation of MBD1 
foci with 5meC foci. Trypsin showed this co-localisation of 5meC and MBD1 within 
DNA-rich foci (within the yellow boxes). 
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5.3.3. The effect of DNA damage on heterochromatin in MEFs  
 
The pattern of heterochromatin within nuclei was examined in each experimental 
model. The amount of HP1-β, the heterochromatic marker, detected in each nuclei 
significantly decreased as an immediate (1h) response to UV-induced DNA damage 
(p<0.0001) (Figure 5-15A). In model 2, the level of HP1-β staining was more than two-
fold higher after UV (for 15 sec, Model 2) compared to untreated control cells 
(p<0.0001) (Figure 5-15B). The level of HP1-β staining was again found to be higher 
after 24h of doxorubicin treatment compared to untreated cells (p<0.0001) (Model 3) 
(Figure 5-15C). HP1-β localisation throughout the nucleus was also affected by DNA 
damage. Focal accumulation of heterochromatin was lost to some extent in model 1(UV 
12min) (p<0.0001) (Figure 5-15D), but was increased in model 2 (48h after UV 
(15sec)) (p<0.0001) (Figure 5-15E). Doxorubicin also caused a small but significant 
increase in the number of nuclei with predominant focal localisation of HP1-β (p<0.05) 
(Figure 5-15F). Nuclei were significantly larger at 48h after UV (p<0.0001) and after 
24h with doxorubicin (p<0.01) compared to untreated cells (Figure 5-16B and C), 
however, no alteration in the nucleus size was observed within 1h of UV treatment 
(p>0.05) (Figure 5-16A). The mechanisms affecting nuclear volume were not explored. 
It is known that the cellular differentiation status and extent of nuclear condensation 
during repair processes may affect the size in nucleus (Smetana et al., 2013; Webster et 
al., 2009). Prolonged culture of cells (such model 2) after DNA damage may cause 
further enlargement of nucleus size as cells in long culture may undergo senescence by 
increased aging (Pichugin et al., 2011) and/or by DNA damage (Zglinicki et al., 2005).  
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Figure 5-15. The changes in the pattern of heterochromatin after DNA damage.  
A, B and C show the amount of HP1-β in models 1, 2 and 3, respectively. D, E and F 
show the proportion of nuclei with predominantly focal HP1-β staining (%).  Graphs 
(A-C) represent +/- s.e.m of at least three independent replicates. At least 100 nuclei 
were analysed per treatment in each replicate. (n, total number of nuclei analysed) * 
p<0.05, **** p<0.0001  
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Figure 5-16. Nucleus size of MEFs after DNA damage. 
A, B and C show the average size of nuclei (pixels) after DNA damage of experimental 
models 1, 2 and 3, respectively. (A) Model 1 (12min UV by 1h), (B) Model 2 (15sec UV 
by 48h) and (C) Model 3 (doxorubicin-50nM by 24h). (A) No difference was seen after 
UV in model 1 compared to untreated cells. But nuclei were bigger after DNA damage 
in models (B) 2 and (C) 3. Graphs represent +/- s.e.m of at least three independent 
replicates. At least 90 nuclei were analysed per treatment in each replicate.** p<0.01, 
**** p<0.0001  
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5.3.4. The effect of DNA damage on the pattern of MBD1 staining within 
heterochromatin  
 
Distinct accumulation of cytosine methylation within nuclear foci was predominantly 
associated with heterochromatin, but MBD1 seemed to have a different localisation. 
Thus, the behaviour of MBD1 in cells with DNA damage was assessed by co-staining 
of MBD1 and HP1-β with Hoechst-intense foci. These Hoechst-intense foci were 
classified as being: (i) stained for HP1-β and MBD1 (+/+), (ii) stained for HP1-β, not 
stained for MBD1 (+/-), (iii) no staining for HP1-β but stained for MBD1 (-/+), or (iv) 
no staining for either HP1-β or MBD1 (-/-).  
In model 1, a majority of Hoechst-intense foci in untreated cells were not stained with 
MBD1 protein but did stain for HP1-β (p<0.0001) (staining pattern +/-) (across yellow) 
(Figure 5-17A and C). UV changed this pattern, with an increase in the number of foci 
with neither HP1-β or MBD1 (p<0.05) (staining pattern -/-) (across blue) (Figure 5-17B 
and C). Interestingly UV also increased the number of foci with both co-localisation of 
those antigens (staining pattern +/+, across red) compared to untreated cells (p<0.05) 
(Figure 5-17B and C) and a decrease in those showing only HP1-β.  
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Figure 5-17. Nuclear localisation pattern of MBD1 and HP1-β in DNA damage 
(Model 1). 
Quiescent cells were treated with 12 min UV, and fixed at 1h after UV. Cells were 
double-stained for MBD1 and HP1-β and counterstained with Hoechst. A and B show 
representative images for untreated and UV-treated cells, respectively. Scale 10 micron. 
Existence or absence of MBD1 and HP1-β staining was shown as + and -. Yellow, red 
and blue boxes indicate representative staining of Hoechst-foci (+/-), (+/+) and (-/-) 
respectively. C shows the number of DNA-rich foci (by Hoechst) co-stained with or 
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without HP1-beta and/or MBD1 in each cell. At least 100 foci analysed per treatment in 
each replicate. * p<0.05, ** p<0.01, **** p<0.0001 
 
In model 2, UV treatment increased the number of Hoechst-intense foci that were 
decorated with HP1-β alone (staining +/- ) (across yellow) and those decorated with 
both HP1-β and MBD1 (p<0.0001) (staining pattern +/+) (across white) (Figure 5-18A-
C). However, the number of Hoechst-intense foci without HP1-β and MBD1 (staining 
pattern -/-) decreased 48h after UV (p<0.0001) (across blue). 
In model 3, the distribution of these antigens was more variable. Doxorubicin decreased 
the number of DNA-foci stained without HP1-β and MBD1 compared to untreated 
control cells (p<0.05) (staining pattern -/-) (across blue) (Figure 5-19A-C) but was 
otherwise without effect. 
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Figure 5-18. Nuclear localisation pattern of MBD1 and HP1-β in DNA damage 
(Model 2). 
Quiescent cells were treated with 15sec UV and fixed at 48h after UV. Control cells 
were untreated. Cells were double-stained for MBD1 and HP1-β and counterstained 
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with Hoechst. A and B show the representative images for untreated and UV-treated 
cells, respectively. Scale 10 micron. Existence or absence of MBD1 and HP1-β staining 
was shown as + and -. Blue, yellow and white boxes indicate representative staining (-/-
), (+/-) and (+/+) respectively. C shows the number of DNA-rich foci (by Hoechst) co-
stained with or without HP1-beta and/or MBD1 in each cell. At least 95 foci analysed 
per treatment in each replicate. *** p<0.001, **** p<0.0001 
133 
 
 
 
Figure 5-19. Nuclear localisation pattern of MBD1 and HP1-β in DNA damage 
(Model 3). 
Proliferative cells were treated with doxorubicin (50nM) for 24h. Control cells were 
untreated. Cells were double-stained for MBD1 and HP1-β and counterstained with 
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Hoechst. A and B show the representative images for untreated and doxorubicin-treated 
cells, respectively. Scale 10 micron. Existence or absence of MBD1 and HP1-β staining 
was shown as + and -, respectively. Yellow, white and blue indicate representative 
staining (+/-), (+/+), and (-/-) respectively. C shows the number of DNA-rich foci (by 
Hoechst) co-stained with or without HP1-beta and/or MBD1 in each cell. At least 125 
foci analysed per treatment in each replicate. * p<0.05 
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5.4. DISCUSSION  
The results of this chapter showed that the extent of trypsin-sensitive masking of the 
5meC antigen varied with the proliferative status of MEFs. It also showed that much of 
the masked 5meC was associated with heterochromatin. It is known that 
heterochromatin can be dynamic epigenetic structure and that induction of DNA 
damage can cause changes in a cell’s heterochromatin. In this chapter DNA damage was 
shown to reduce (but not completely remove) the level of trypsin sensitive masking of 
5meC, particularly within heterochromatic foci.  
The study found that the DNA damage induced by either UV-irradiation or doxorubicin 
both caused more of the 5meC associated with heterochromatin to be solvent-exposed 
and accessible to antibodies after acid-induced denaturation alone. The results show that 
while the detection of 5meC within heterochromatic foci increased after DNA damage, 
this did not result in complete unmasking of this pool of the epitope. Trypsin treatment 
generally resulted in some further recovery of the antigen within heterochromatin. This 
observation is consistent with the known phenomenon of some relative decondensation 
of heterochromatin occurring in response to DNA damage. It is generally reasoned that 
this facilitates the access of repair factors to damaged DNA sites (Baldeyron et al., 
2011; Terzoudi et al., 2011). Displacement of heterochromatin proteins from chromatin 
is required for repair factor access (Dinant and Luijsterburg, 2009; Soria et al., 2012). 
However, the initial steps of DNA damage repair appear in compact domains of 
chromatin. For instance, HP1 family proteins (HP1-α, β and γ) recruit to a range of 
damage sites (Baldeyron et al., 2011; Dinant and Luijsterburg, 2009; Soria et al., 2012), 
such DSBs (Luijsterburg et al., 2009). Changes in the abundance and mobilisation of 
HP1-β in heterochromatin occurred after laser treatment (Ayoub et al., 2008; Ayoub et 
al., 2009). Shortly after ionizing radiation, mobilisation of HP1-β resulted in the binding 
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to histone H3 methylated on lysine 9 (H3K9me), and promoted the phosphorylation of 
H2A.X. Therefore, HP1-β can play a role for initiating DNA repair (Ayoub et al., 
2008). These dynamic changes in heterochromatin structure induced by DNA damage 
may result in an increased level of solvent exposure of the 5meC and if so could 
account for the increased acid-sensitive staining of 5meC in damaged cells.  
Staining of MEFs with the marker of heterochromatin, HP1-β, confirmed that DNA 
damage caused marked changes in heterochromatin. UV-irradiation caused a short-term 
reduction in HP1-β staining but by 48h after exposure there was a marked increase 
relative to untreated controls. This increase corresponded with an increase in the extent 
of chromatin condensation as assessed by Hoechst staining intensity. Doxorubicin 
treatment caused a similar response, although to a smaller extent. It is noteworthy, 
however, that while all DNA damage treatments caused an increase in the solvent-
exposure of acid-sensitive 5meC, in cells soon after UV-treatment this was 
accompanied by reduced HP1-β and in long-term after the UV with an increase in HP1-
β. These results show that while changes in heterochromatin were occurring the level of 
HP1-β staining itself was not a predictor of the level of solvent exposure of 5meC. The 
molecular features of heterochromatin that determine trypsin-sensitive masking of 
5meC require further investigation. 
This chapter defined the effect of some form of genotoxic stressors on the level of 
solvent exposure of  both 5meC and MDB1. The changes detected after DNA damage 
represent the extent of detectable pools of both antigens rather than the real changes in 
the level of DNA methylation or in chromatin conformation after DNA damage. Further 
investigation for the total levels of DNA methylation by quantitative methods can 
address this concern. However the results have provided new insights into the 
methylation dynamics after DNA damage which induces the recruitment of proteins that 
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have different responses to antigenic retrieval. Future studies are needed for the 
identification and characterisation of these DNA repair-related proteins so provide more 
details of DNA methylation machinery.  
An unexpected finding of this study was that MBD1 showed a low level of co-
localisation with 5meC. It was also shown that MBD1 had a relatively poor association 
with heterochromatic foci (as identified by either HP1-β staining or Hoechst-intense 
foci). Many Hoechst staining and/or HP1-β staining foci were not decorated by anti-
MBD1. Each of the DNA damage models tested caused an increase in the association of 
MBD1 with heterochromatin, but it still remained a minor component. A high level of 
independence of localisation of MBD1 from 5meC and heterochromatin may suggest 
that some pools of MBD1 behave differentially than 5meC in response to DNA damage. 
However, the levels of both MBD1 and 5meC increased after DNA damage (model 
1,2,3) regardless antigenic retrieval. These results can suggest broader functions of 
MBD1 and point to the further investigation how MBD1 is regulated after DNA 
damage.    
The results show an unexpected heterogeneity in the structure and composition of 
heterochromatic foci in MEFs and illustrate how cell stressors can further promote this 
heterogeneity. The demonstration of the differing staining patterns between 5meC and 
MBD1 and the exacerbation of this by genotoxic stressors, further points to the need for 
caution in the use of 5meC binding proteins as a reliable means of identify 5meC 
patterns and levels in cells. MBD1 has been widely used as an alternative measurement 
of global 5meC (Badran et al., 2011; Morita et al., 2012; Zhang et al., 2012a). A EGFP-
MBD fusion protein was used as an indicator of genomic DNA methylation in living 
cells and considered to co-localise with methylated DNA (Kobayakawa et al., 2007). 
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However, the current result cautions that thorough validation of such approaches is 
required. 
The marked changes in 5meC antigen detected in cells under the different experimental 
conditions used here indicate that the local regions of the genome marked by 5meC are 
likely to be highly dynamic and this may reflect changes in the epigenetic state of the 
cells. Although trypsin-digestion caused an increased recovery of 5meC staining in 
almost all settings, it is not possible to assume at this time that this represents all the 
5meC in the cell, and this question warrants further investigation by suitable chemical 
measures of whole-cell 5meC, and the dynamic changes in the chromatin structure of 
the cell. The extensive recruitment of 5meC to heterochromatic DNA, and the changes 
in heterochromatin structure induced by DNA damage, point to the potential for 
profound changes in the solvent exposure of 5meC. Given that the actions of 5meC on 
gene expression are mediated by the capacity of 5meC to act as a docking site for a 
range of binding proteins, such changes in solvent exposure may well have functional 
significance. These observations provide guidance for further investigation of this 
question.   
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6. CHAPTER 6: GENERAL DISCUSSION 
This thesis shows that conventional immunologically-based methods for assessing 
5meC levels within cells can underestimate both the levels of expression and the 
patterns of localisation of the antigen within the cells. It shows that significant levels of 
5meC antigen are subjected to trypsin-sensitive masking which is not revealed by acid-
induced denaturation of chromatin that has been the standard approach for the last few 
decades. Furthermore, the extent of this masking varied with the cell’s state, including 
its proliferative state, ontological age and responses to DNA damage. These marked 
changes in the levels of detectable 5meC could easily be interpreted as changes in the 
methylation state and create the illusion of demethylation or re-methylation in response 
to specific changes in the cell’s environment.  
These observations extend recent findings that reports of active global demethylation of 
the zygotic genome are accounted for by progressive antigenic masking during zygotic 
maturation. It shows that such changes can also occur in a well-defined somatic cell 
model. The results show that all immunological staining methods for assessing 5meC 
should be fully validated for each cell type and conditions being used to assess whether 
trypsin-sensitive masking occurs and if so ensure that the full of antigen-retrieval is 
achieved as part of the staining protocol. Antigenic retrieval using trypsin can also be 
considered for the immunostaining procedures of 5meC modifications. But it is 
noteworthy that the extent and nature of antigenic masking 5meC and 5hmC varied 
considerably in the zygote (Li and O'Neill, 2013). Unlike 5mC, 5hmC was the subject 
of very little trypsin-sensitive masking in the zygote and this further indicate that the 
two modification are largely represented within regions of chromatin that have 
markedly different structure and conformation.  
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The recent observation that chemical methods for assaying 5meC (bisulfite conversion 
and differential restriction analysis) suffer from the technical limitation of not being 
capable of distinguishing between all of the modifications of cytosine (5meC, 5hmC, 
5fC, 5caC) greatly limits and complicates the usefulness of these techniques. Most 
reported methylomes, therefore, actually describe the net levels of all modifications of 
cytosine rather than 5meC as previously thought. It is now being recognised that each of 
these modification produces their own epigenetic information to the cell and hence, the 
summation of these modifications is likely to create considerable confusion in 
interpretation of epigenetic programming. These limitations of ‘gold-standard’ chemical 
analyses mean that immunological-based methods provide an important additional 
analytical tool because they are readily able to distinguish between these various 
modifications. The results of this thesis used an anti-5meC antibody (Clone 33D3, AbD 
Serotec, Cat. No. MCA2201) with high specificity for 5meC (Li and O'Neill, 2012). It 
does not cross-react with 5hmC and is the most widely used antibody for the purpose 
(Bracht et al., 2012; Li and O'Neill, 2013).  
Immune-based methods have the disadvantage that they do not readily provide base 
level analysis. The use of antibodies in immunoprecipitation assays (such as MeDIP-
seq) can be used to provide some regional information (300-1000bp) on methylation but 
does not provide true base level analysis. It is a relatively inefficient form of analysis 
meaning that high quantity of DNA are required, limiting its use. Although these high-
throughput methodologies such MBD-seq (e.g. MethylMiner) can reveal the degree of 
methylation using MBD domain of MeCP2 protein binding to the methylated genome 
(Meyer et al., 2013; Trimarchi et al., 2012), MeCP2 was shown to have a lower binding 
affinity to methylated DNA than MBD1 protein (Badran et al., 2011). But the findings 
of this PhD thesis suggest rethinking the reliability of such methodologies for 
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determination of cytosine methylation. However, immunolocalisation techniques have 
the advantage of detecting changes in the localisation of methylated regions of 
chromatin within individual cells.  
 
There are a number of lines of evidence that implicate 5meC in heterochromatin 
formation (Akhmanova et al., 2000; Hajkova et al., 2008; Kang et al., 2001; 
Wongtawan et al., 2011). For instance, cytosine methylation is used as a 
heterochromatin marker in preimplantation embryos (Wongtawan et al., 2011) and in 
embryonic stem cells (Fazzio and Panning, 2010), and chromatin changes are associated 
with the loss of methylation in primordial germ cells (Hajkova et al., 2008). The level of 
methylation decreased in euchromatin, whereas it was maintained in heterochromatin 
(Kang et al., 2001). A high level of cytosine methylation is found within constitutive 
heterochromatin which contains minor (centromeric heterochromatin) and major 
(pericentromeric heterochromatin) satellite DNA (Maison et al., 2010; Mattei and 
Luciani, 2003). The loss of cytosine methylation is involved in the accumulation of 
transcripts of minor and/or major satellite. These accumulation are observed upon such 
cellular stress and differentiation (Eymery et al., 2009). However no accumulation of 
centromeric heterochromatin (minor satellite DNA) transcripts within the nucleus is 
detected in human heterochromatin so far but observed in mouse heterochromatin 
(Eymery et al., 2009). Since HP1 isoforms are predominantly associated with 
centromeric heterochromatin (Maison et al., 2010), the structure of mouse 
heterochromatin likely appears to be, at least for the present time, more pronounced 
sensor for the investigation of epigenetic regulation within heterochromatin. Cytosine 
methylation also induces 3D conformational changes in DNA helix, called the E-DNA 
structure (Vargason et al., 2000). Thus, 5meC may provide important topological 
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information to chromatin that assist in determining the large scale conformation of the 
nucleus.  
The methyl group attached to the 5´-carbon within cytosine lies within the major groove 
of the DNA double helix. This position might be expected to allow the antigen to be 
accessible by antibodies, but the extensive coiling and compaction of DNA (Okuwaki 
and Verreault, 2004; Vargason et al., 2000) and its decoration by a host of proteins 
means that little 5meC is detected in chromatin in its native state. The basic unit of 
organisation of the genome is the nucleosome, where DNA is wrapped around a core set of 
proteins. A nucleosome can be organised into progressively more compact structures, 
including 10 and 30nm fibers (Kouzarides, 2007; Li, 2002; Luger et al., 1997; Woodcock 
and Ghosh, 2010). This complexity is further enhanced by the binding of a diverse 
proteome of chromatin and non-chromatin proteins that provide both structural and 
functional heterogeneity to the genome. Some of these proteins specifically recognise 
and bind to mCpG (Bogdanović and Veenstra, 2009). This complexity provides many 
potential opportunities for the mCpG epitope to be masked from antibodies. The 
observations of dynamic changes in the levels of solvent exposure of 5meC are entirely 
consistent with the known highly dynamic nature of chromatin structure and 
conformation.  
This study shows an unexpected complexity in heterochromatin structure in fibroblasts. 
There was clearly heterogeneity in the level of solvent exposure of 5meC, and this 
further varied with the cell’s growth state and response to genotoxic stress. There was 
heterogeneity in the association of MBD1 with heterochromatin and also its level of 
solvent exposure. The study does not reveal whether this heterogeneity has functional 
significance, but highlights a new avenue for further research. The findings suggest 
cytosine methylation within the genome exist as multiple populations which have 
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different response to antigenic retrieval techniques. It is known that a range of proteins, 
such MBD1, bind to 5meC and these protein complexes contribute to the three-
dimensional structure of chromatin (Badran et al., 2011; Fournier et al., 2011). They 
might also serve to mask 5meC within the chromatin from antibodies. This study shows 
MBD1 protein had a consider level of localisation that was independent of both 
methylated cytosine and heterochromatin. This was most obvious after standard acid 
denaturation of chromatin. Thus, chromatin conformation causes a significant level of 
trypsin-sensitive masking of both antigens. A systematic method by the assessment of 
immunofluorescence images (in particular confocal images) which uses “a line of 
interest” throughout the nucleus can provide a detailed analysis of regionalized 
differences in the levels of solvent exposure of 5meC and MBD1 (Li and O'Neill, 
2013).  
MBD1 has been widely used as a proxy measure for 5meC and also as a ‘bait’ for 
selection sequences for base-level analysis of methylation. This study makes the 
surprising finding that like 5meC, there was significant trypsin-sensitive masking 
MBD1 in fibroblasts. This differed from the situation in the early embryo (Li and 
O'Neill, 2012) and indicates that MBD1 detection is also dependent upon the 
configuration of chromatin within the cell. Methyl-CpG binding proteins play a role in 
regulating conformational changes in chromatin (Bird and Wolffe, 1999). MeCP2 
protein is present in peri-nucleolar heterochromatin in neurons (Akhmanova et al., 
2000). In heterochromatin structure MBD1 can be associated with histone methylation 
(Fujita et al., 2003; Sarraf and Stancheva, 2004), HP1-α protein (Fujita et al., 2003), a 
chromatin assembly factor (Reese et al., 2003), or a heterochromatin-associated protein 
(Bierne et al., 2009). Some MBD1 foci were found not co-localise with heterochromatin 
in this thesis. This may represent the existence of MBD1 in euchromatin, since MBD1 
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is also capable of binding to euchromatin (Fujita et al., 1999). This study shows that not 
all MBD1 staining faithfully reflects the 5meC localisation in fetal fibroblasts. This 
result points to a requirement to fully validate its suitability as a proxy for 5meC.  
DNA damage can also change chromatin conformation. Shortly after DNA damage, the 
nucleoprotein complexes undergo dynamic arrangements, such as unfolding and 
disassembly, followed by further stages for assembly and refolding after completion of 
DNA repair (Terzoudi et al., 2011). This suggests a possible explanation how DNA 
methylation in the experimental models might be reorganised within the chromatin 
during DNA repair, so cytosine methylation and MBD1 can reposition within diffuse 
(unfolded) or focal (folded) nuclear regions while chromatin is being unpackaged and 
repackaged during repair processes. It may also suggest that local DNA repair within 
packaged methylation requires chromatin relaxation, since chromatin proteins can serve 
as a barrier to partially protect the genome from damage (Luijsterburg and van Attikum, 
2011). The results do not provide a definitive explanation of how the processes of DNA 
damage/repair cause the large changes in 5meC localisation and detection, but serve to 
further illustrate how changes in the cells homeostatic can cause marked changes in the 
solvent exposure of 5meC within cells.  
The study has not undertaken base-level analysis of changes in methylation under these 
experimental conditions since this was not part of the aim. Thus, it cannot be 
determined whether the changes in solvent exposure of 5meC with changes in the cells 
growth status reflect changes in the localisation of 5meC within the genome, or changes 
in localisation the same methylated CpGs regions within chromatin, or a combination of 
both. In the future the combined use of fully validated immunological detection 
methods with base-levels analyses of the full range of modification to cytosine will be 
valuable tools for determine the regulation and roles of differential covalent 
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modification of cytosine in gene function and epigenetic control for development and 
disease.  
In conclusion, this thesis presents a detailed investigation for the improvement of 
accurate detection of global DNA methylation using antibody-based methods, and this 
is the first study showing that antigenic unmasking of DNA methylation with tryptic 
digestion revealed a heterogeneity in nuclear arrangements of methylation (5meC and 
MBD1) in somatic cells. These are accompanied by the changes in heterochromatin 
during DNA damage. The results suggest a new model of DNA methylation within the 
mammalian genome. This represents multiple populations of genome which have 
different response to antigenic retrieval induced by some conditions, such cell growth 
and DNA damage. The further experiments need to investigate the range of methylation 
pattern in intra-nuclear regions and also the association of 5meC metabolites with this. 
These regions likely include chromatin-associated proteins which mask DNA 
methylation in some settings. The identification and characterisation of masking 
proteins within these genomic regions will provide detailed understanding in 
methylation dynamics.  
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8. APPENDIX: GENERAL EQUIPMENT USED 
 Autoclave (S-B Autoclaves by I.L.A.T Pty. Ltd) 
 Centrifuges (Beckman GPR and Clements GS150) 
 CO2 Incubator (Forma Scientific and Thermoscientific, Hepa Class 100 supplied 
by Biolab Pty. Ltd) 
 Flow cytometer (BD FACSCalibr, BDIS San Jose Ca. USA) 
 Freezer (-20°C) (Westinghouse-393) 
 Freezer (-80°C) (Sanyo VIPTIM Series supported by Quantum Scientific) 
 Fridges (Westinghouse and Skope) 
 Incubator (without 5%CO2) (Qualtex) 
 Laminar flow cabinet (Gelaire Pty. Ltd) 
 Light microscopes (Olympus B061 and Nikon TMS) 
 Liquid nitrogen tank (Taylor-Wharton ABS-20K, Australia Pty. Ltd) 
 Microbalance (Cahn C-33 Series) 
 Milli-Q Water (Merck Milipore, Germany) 
 pH meter (PHM 61 Laboratory pH meter) 
 Shaker (Flow Laboratories , Titertek plate shaker)  
 Stirrer (Townson and Mercer Pty. Ltd) 
 Vortex (Lab-Line Instruments, Inc., Super Mixer, Cat. No. 1291) 
 Warm Plate (Thermoline Australia, Laboratory warming tray) 
 Water Bath (Ratek) 
 Weighers (Sauter R300 and Mettler AE166/ Delta Range) 
 
